WO1998044113A1 - Secreted proteins and polynucleotides encoding them - Google Patents

Secreted proteins and polynucleotides encoding them Download PDF

Info

Publication number
WO1998044113A1
WO1998044113A1 PCT/US1998/006176 US9806176W WO9844113A1 WO 1998044113 A1 WO1998044113 A1 WO 1998044113A1 US 9806176 W US9806176 W US 9806176W WO 9844113 A1 WO9844113 A1 WO 9844113A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
polynucleotide
protein
sequence
Prior art date
Application number
PCT/US1998/006176
Other languages
French (fr)
Inventor
Kenneth Jacobs
John M. Mccoy
Edward R. Lavallie
Lisa A. Racie
David Merberg
Maurice Treacy
Vikki Spaulding
Michael J. Agostino
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to EP98912112A priority Critical patent/EP0970209A1/en
Priority to CA002285447A priority patent/CA2285447A1/en
Priority to AU65908/98A priority patent/AU6590898A/en
Priority to JP54187998A priority patent/JP2002512512A/en
Publication of WO1998044113A1 publication Critical patent/WO1998044113A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:l from nucleotide 170 to nucleotide 322; the nucleotide sequence of SEQ ID NO:l from nucleotide 218 to nucleotide 322; the nucleotide sequence of SEQ ID NO:l from nucleotide 1814 to nucleotide 2355; the nucleotide sequence of the full-length protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 1
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2;
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • nucleotide 102 from nucleotide 1295; the nucleotide sequence ot SEQ ID NO:3 from nucleotide 162 to nucleotide 1295; the nucleotide sequence of SEQ ID NO:3 from nucleotide 804 to nucleotide 1184; the nucleotide sequence of the full-length protein coding sequence of clone crll62_25 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone crl 162_25 deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 236 to amino acid 361.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 351 to nucleotide 842; the nucleotide sequence of SEQ ID NO:5 from nucleotide 687 to nucleotide 842; the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 689; the nucleotide sequence of the full-length protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 113.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • amino acid sequence of SEQ ID NO:6 comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:6; and (d) the amino acid sequence encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
  • protein comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 113.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 40 to nucleotide 1503; the nucleotide sequence of SEQ ID NO:9 from nucleotide 863 to nucleotide 1377; the nucleotide sequence of the full-length protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10 from amino acid 277 to amino acid 446.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • protein comprises the amino acid sequence of SEQ ID NO:10 or the amino acid sequence of SEQ ID NO:10 from amino acid 277 to amino acid 446.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:ll from nucleotide 85 to nucleotide 450; the nucleotide sequence of SEQ ID NO:ll from nucleotide 217 to nucleotide 450; the nucleotide sequence of the full-length protein coding sequence of clone eh61_l deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone eh61_l deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12 from amino acid 9 to amino acid 94.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • amino acid sequence of SEQ ID NO:12 comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO: 12; and (d) the amino acid sequence encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
  • protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence of SEQ ID NO:12 from amino acid 9 to amino acid 94.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 15 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:15;
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:14 from nucleotide 900 to nucleotide 1073; the nucleotide sequence of SEQ ID NO:14 from nucleotide 544 to nucleotide 1022; the nucleotide sequence of the full-length protein coding sequence of clone fg265_l deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone fg265_l deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15 from amino acid 1 to amino acid 41.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:16 from nucleotide 119 to nucleotide 2440; the nucleotide sequence of SEQ ID NO:16 from nucleotide 200 to nucleotide 2440; the nucleotide sequence of SEQ ID NO:16 from nucleotide 460 to nucleotide 1153; the nucleotide sequence of the full-length protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:17 from amino acid 115 to amino acid 345.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • protein comprises the amino acid sequence of SEQ ID NO: 17 or the amino acid sequence of SEQ ID NO:17 from amino acid 115 to amino acid 345.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19 from amino acid 21 to amino acid 69.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:21; (j) a polynucleotide which is an allelic variant of a polynucleotide of
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 99 to nucleotide 536; the nucleotide sequence of SEQ ID NO:20 from nucleotide 1 to nucleotide 370; the nucleotide sequence of the full-length protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21 from amino acid 1 to amino acid
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • protein comprises the amino acid sequence of SEQ ID NO:21 or the .amino acid sequence of SEQ ID NO:21 from amino acid 1 to amino acid 90.
  • the polynucleotide is operably linked to an expression control sequence.
  • the invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein. Processes are also provided for producing a protein, which comprise:
  • the protein produced according to such methods is also provided by the present invention.
  • Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.
  • Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier.
  • Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
  • Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
  • Figures 1 A and IB are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.
  • nucleotide and amino acid sequences are reported below for each clone and protein disclosed in the present application.
  • the nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence.
  • the amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
  • a "secreted” protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence.
  • "Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed.
  • “Secreted” proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
  • bl209_10 A polynucleotide of the present invention has been identified as clone "bl209_10".
  • bl209_10 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • bl209_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bl209_10 protein").
  • nucleotide sequence of bl209_10 as presently determined is reported in SEQ ID NO:l. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bl209_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2.
  • Amino acids 4 to 16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17, or are a transmembrane domain.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone bl209_10 should be approximately 2400 bp.
  • the nucleotide sequence disclosed herein for bl209_10 was searched against the
  • bl209_10 demonstrated at least some similarity with sequences identified as AA522436 (ng30g05.sl NCI_CGAP_ Co3 Homo sapiens cDNA clone IMAGE 936344), L06147 (Human (clone SY11) golgin-95 mRNA, complete eds), N29620 (yw67d06.sl Homo sapiens cDNA clone 257291 3'), N41622 (yw67d06.rl Homo sapiens cDNA clone 257291 5'), N80172 (za65g07.sl Homo sapiens cDNA clone 297468 3'), and U35022 (Rattus norvegicus cis-Golgi matrix protein GM130 mRNA, complete eds).
  • the predicted amino acid sequence disclosed herein for bl209_10 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted bl209_10 protein demonstrated at least some similarity to sequences identified as M34651 (immediate-early protein [Suid herpesvirus]). Based upon sequence similarity, bl209_10 proteins and each similar protein or peptide may share at least some activity.
  • the TopPredll computer program predicts N potential transmembrane domains within the bl209_10 protein sequence, one around amino acid X and another around amino acid Y of SEQ ID NO:2.] [The nucleotide /amino add sequence of bl209_10 indicates that it may contain an Alu repetitive element.]
  • crll62_25 protein from a human fetal brain cDNA lbrary.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone crll62_25 should be approximately 3700 bp.
  • crll62_25 demonstrated at least some similarity with sequences identified as H14720 (ym24b05.rl Homo sapiens cDNA clone 48883 5'), H15268 (ym30dll.rl Homo sapiens cDNA clone 499045'), and N45514 (yy59g07.rl Homo sapiens cDNA clone 2778845').
  • the predicted amino acid sequence disclosed herein for crll62_25 was searched against the GenPept, GeneSeq, and SwissProt amino acid sequence databases using the BLASTX search protocol.
  • the predicted crll62_25 protein demonstrated at least some similarity to sequences identified as D12612 (poliovirus receptor gene [Cercopithecus aethiops]), D26156 (hSNF2b; transcriptional activator [Homo sapiens], L12589 (B-lymphocyte activation antigen 7 [Mus museums]), P51532 (POSSIBLE GLOBAL TRANSCRIPTION ACTIVATOR SNF2L3 ( OR SNF2-BETA OR BRG-1) [Homo sapiens]), R07130 (H20B receptor), U29175 (transcriptional activator (BRG1)) [Homo sapiens]), X57516 (poliovirus receptor alpha [Homo sapiens]), X60958 (B lymphocyte activation antigen [Mus musculus]), X64116 (
  • crll62_25 proteins and each similar protein or peptide may share at least some activity.
  • the TopPredll computer program predicts an additional potential transmembrane domain at the carboxy terminus of the crll62_25 protein sequence, centered around amino acid 342 of SEQ ID NO:4.
  • dh40_3 A polynucleotide of the present invention has been identified as clone "dh40_3".
  • dh40_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • dh40_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dh40_3 protein").
  • nucleotide sequence of dh40_3 as presently determined is reported in SEQ ID NO:5. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dh40_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.
  • Amino acids 100 to 112 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 113, or are a transmembrane domain.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone dh40_3 should be approximately 3000 bp.
  • the nucleotide sequence disclosed herein for dh40_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • dh40_3 demonstrated at least some similarity with sequences identified as AG005063 (Homo sapiens genomic DNA, 21q region, clone T1957SpNll), Z67586 (H.sapiens DNA segment containing (CA) repeat), and Z74023 (Human DNA sequence from cosmid LUC A3 on chromosome 3p21.3. contains ESTs).
  • dh40_3 proteins and each similar protein or peptide may share at least some activity.
  • the TopPredll computer program predicts an additional potential transmembrane domain within the dh40_3 protein sequence at the extreme carboxy terminus of SEQ ID NO:6.
  • di39_9 A polynucleotide of the present invention has been identified as clone "di39_9".
  • di39_9 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • di39_9 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "di39_9 protein").
  • the nucleotide sequence of di39_9 as presently determined is reported in SEQ ID
  • amino acids 7 to 19 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone di39_9 should be approximately 3000 bp.
  • di39_9 demonstrated at least some similarity with sequences identified as AA249116 (hfe0042.seq.F Human fetal heart, Lambda ZAP Express Homo sapiens cDNA 5'), AA598667 (ae40a05.sl Gessler Wilms tumor Homo sapiens cDNA clone 8982563'), N53166 (yv56ell.sl Homo sapiens cDNA clone 2467643'), N80292 (za96h08.sl Homo sapiens cDNA clone 3004473'), T86182 (JTV1 coding sequence), U24169 (Human JTV-1 OTV-1) mRNA, complete eds), U38964 (Human PMS2 related (hPMSR2) gene, complete
  • the predicted amino acid sequence disclosed herein for di39_9 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted di39_9 protein demonstrated at least some similarity to sequences identified as U24169 (JTV-1 [Homo sapiens]), U38964 (hPMSR2 [Homo sapiens]), and W25776 (JTV1 protein).
  • the positioning of the regions of similarity to hPMSR2 and JTV-1 relative to each other in the di39_9 sequence is quite similar to that of the JTV-1 and PMS2 sequences in the human genome.
  • di39_9 proteins and each similar protein or peptide may share at least some activity.
  • the TopPredll computer program predicts two additional potential transmembrane domains within the di39_9 protein sequence, one centered around amino acid 160 and another around amino acid 200 of SEQ ID NO:8.
  • dt674_2 A polynucleotide of the present invention has been identified as clone "dt674_2".
  • dt674_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • dt674_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dt674_2 protein").
  • nucleotide sequence of dt674_2 as presently determined is reported in SEQ ID NO:9. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dt674_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone dt674_2 should be approximately 3500 bp.
  • nucleotide sequence disclosed herein for dt674_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
  • dt674_2 demonstrated at least some similarity with sequences identified as T06736 (EST04625 Homo sapiens cDNA clone HFBDX78).
  • the predicted amino acid sequence disclosed herein for dt674_2 was searched against the GenPept and GeneSeq amino add sequence databases using the BLASTX search protocol.
  • the predicted dt674_2 protein demonstrated at least some similarity to sequences identified as Z72807 (ORF YGR023w [Saccharomyces cerevisiae]). Based upon.sequence similarity, dt674_2 proteins and each similar protein or peptide may share at least some activity.
  • the nucleotide sequence of dt674_2 indicates that it may contain at least one copy of one or more repetitive elements.
  • a polynucleotide of the present invention has been identified as clone "eh61_l".
  • eh61_l was isolated from a human adult blood (peripheral blood mononuclear cells treated with granulocyte-colony stimulating factor in vivo) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • eh61_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "eh61_l protein").
  • nucleotide sequence of the 5' portion of eh61_l as presently determined is reported in SEQ ID NO:ll. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:12.
  • the predicted amino acid sequence of the eh61_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12.
  • Amino acids 32 to 44 are a predicted leader /signal sequence, with the predicted mature amino acid sequence beginning at amino acid 45, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of eh61_l, including the polyA tail, is reported in SEQ ID NO: 13.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone eh61_l should be approximately 2200 bp.
  • eh61_l The nucleotide sequence disclosed herein for eh61_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. eh61_l demonstrated at least some similarity with sequences identified as AA114131 (zn75g05.sl Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 564056 3' similar to contains Alu repetitive element;contains element
  • H53674 (yu38e03.rl Homo sapiens cDNA clone 236092 5'), L24093 (Gorilla gorilla ADP-ribosyltransferase (NAD+) pseudogene, repeat region), N38129 (19356 Arabidopsis thaliana cDNA clone 219I8T7), T04321 (368 Arabidopsis thaliana cDNA clone), U45981 (Schizosaccharomyces pombe Ste20-related protein kinase (shk2) gene, complete eds), and X97774 (A.thaliana mRNA for light represssible receptor protein kinase).
  • the predicted amino acid sequence disclosed herein for eh61_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted eh61_l protein demonstrated at least some similarity to sequences identified as D10152 (protein tyrosine-serine-threonine kinase [Arabidopsis thaliana]), L24521 (transformation-related protein [Homo sapiens]), and L76191 (interleukin-1 receptor-associated kinase [Homo sapiens]). Based upon sequence similarity, eh61_l proteins and each similar protein or peptide may share at least some activity.
  • the nucleotide sequence of eh61_l indicates that it may contain an Alu repetitive element.
  • fg265_l A polynucleotide of the present invention has been identified as clone "fg265_l".
  • fg265_l was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • fg265_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fg265_l protein").
  • the nucleotide sequence of fg265_l as presently determined is reported in SEQ ID
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone fg265_l should be approximately 3100 bp.
  • fg265_l demonstrated at least some similarity with sequences identified as AA076592 (zm91hl0.rl Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 5453475'), AA482600 (zt34al2.sl Soares ovary tumor NbHOT Homo sapiens cDNA), N23393 (yx83dl2.sl Homo sapiens cDNA clone 268343 3'), R10011 (yf34g05.rl Homo sapiens cDNA clone 128792 5'), R41186 (yf84c08.sl Homo sapiens cDNA clone 293133'), and W87844 (zh68a05.rl Soares
  • fp273 10 A polynucleotide of the present invention has been identified as clone "fp273_10".
  • fp273_10 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • fp273_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fp273_10 protein").
  • nucleotide sequence of fp273_10 as presently determined is reported in SEQ ID NO:16. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fp273_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:17. Amino acids 15 to 27 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28, or are a transmembrane domain.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone fp273_10 should be approximately 3800 bp.
  • the nucleotide sequence disclosed herein for fp273_10 was searched against the
  • fp273_10 demonstrated at least some similarity with sequences identified as R16387 (yf91g01.rl Homo sapiens cDNA clone 29825 5'), R17806 (yg09b06.rl Homo sapiens cDNA clone 317635'), and T65784 (ycllflO.sl Homo sapiens cDNA clone 80395 3' similar to contains LI repetitive element). Based upon sequence similarity, fp273_10 proteins and each similar protein or peptide may share at least some activity.
  • the TopPredll computer program predicts four additional potential transmembrane domains within the fp273_10 protein sequence, centered around amino acids 140, 530, 560, and 720 of SEQ ID NO:17, respectively.
  • the fp273_10 protein has a C-5 cytosine-specific DNA methylase motif.
  • fy243_8 A polynucleotide of the present invention has been identified as clone "fy243_8".
  • fy243_8 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • fy243_8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fy243_8 protein").
  • the nucleotide sequence of fy243_8 as presently determined is reported in SEQ ID NO:18. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fy243_8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:19. Additional open reading frames for fy243_8 are predicted at basepairs 297 to 635, at basepairs 826 to 1014, and at basepairs 1102 to 1248 of SEQ ID NO:18; the predicted amino acid sequences corresponding to the foregoing nucleotide sequences are reported in SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34, respectively. The open reading frame for SEQ ID NO:19 could be joined to those for SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34 if the intervening nucleotide sequences of SEQ ID NO:18 were removed.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone fy243_8 should be approximately 2200 bp.
  • fy243_8 demonstrated at least some similarity with sequences identified as AA121177 (zl88h03.sl Stratagene colon (#937204) Homo sapiens cDNA clone 511733 3'), AA121218 (zl88h03.rl Stratagene colon (#937204) Homo sapiens cDNA clone 511733 5' similar to WP F44B9.5 CE00552), AA126582 (zn86gl2.sl Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565126 3'), R73372 (yll0g08.rl Homo sapiens cDNA clone 157886 5' similar to SP F44B9.5 CE00552), T27033 (NIBT173E09R Infant brain,
  • a polynucleotide of the present invention has been identified as clone "ga205_4".
  • ga205_4 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • ga205_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ga205_4 protein").
  • the nucleotide sequence of ga205_4 as presently determined is reported in SEQ ID NO:20. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ga205_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:21.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone ga205_4 should be approximately 1000 bp.
  • the nucleotide sequence disclosed herein for ga205_4 was searched against the
  • ga205_4 demonstrated at least some similarity with sequences identified as AA075247 (zm86e01.rl Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 544824 5'), AA081273 (zn33el2.sl Stratagene endothelial cell 937223 Homo sapiens cDNA clone 5492623'), AA203476 (zx55e01.rl Soares fetal liver spleen INFLS SI Homo sapiens cDNA clone 446424 5' similar to contains element LI repetitive element), T21011 (Human gene signature HUMGS02293), and U73030 (Rattus norvegicus pituitary tumor-specific transforming factor mRNA, complete eds).
  • ga205_4 The predicted amino acid sequence disclosed herein for ga205_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted ga205_4 protein demonstrated at least some similarity to sequences identified as U73030 (PTTG gene product [Rattus norvegicus]). Based upon sequence similarity, ga205_4 proteins and each similar protein or peptide may share at least some activity.
  • Clones bl209_10, crll62_25, dh40_3, di39_9, dt674_2, eh61_l, fg265_l, fp273_10, fy243_8, and ga205_4 were deposited on March 28, 1997 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98379, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. ⁇ 1.808(b), and the term of the deposit will comply with 37 C.F.R.
  • Each clone has been transfected into separate bacterial cells (E. coli) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/Notl digestion (5' site, EcoRI; 3' site, Notl) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1.
  • the pED6dpc2 vector (“pED6" was derived from pED ⁇ dpcl by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res.
  • the pNOTs vector was derived from pMT2 (Kaufman et al., 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the Ml 3 origin of replication in the Clal site.
  • the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate.
  • the cDNA insert can still be isolated by digestion with EcoRI and Notl. However, Notl will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector.
  • the cDNA may also be expressed from the vectors in which they were deposited. Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
  • oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
  • the design of the oligonucleotide probe should preferably follow these parameters:
  • the oligonucleotide should preferably be labeled with g- 32 P ATP (specific activity 6000
  • Ci/mmole Ci/mmole
  • T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
  • the bacterial culture containing the pool of full-length clones should preferably be thawed and 100 ⁇ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 ⁇ g/ml.
  • the culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth.
  • Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 ⁇ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
  • Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.
  • the filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 ⁇ g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter).
  • the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL.
  • the filter is then preferably incubated at 65°C with gentle agitation overnight.
  • the filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional.
  • the filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.
  • the positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures.
  • the clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.
  • Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention.
  • Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al, Bio /Technology 10, 773-778 (1992) and in R.S. McDowell, et al, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference.
  • Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.
  • fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin.
  • a fusion could be to the Fc portion of an IgG molecule.
  • Other immunoglobulin isotypes may also be used to generate such fusions.
  • a protein - IgM fusion would generate a decavalent form of the protein of the invention.
  • the present invention also provides both full-length and mature forms of the disclosed proteins.
  • the full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone.
  • the mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell.
  • the sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.
  • the present invention also provides genes corresponding to the polynucleotide sequences disclosed herein.
  • Corresponding genes are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and /or amplification of genes in appropriate genomic libraries or other sources of genomic materials.
  • An "isolated gene” is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.
  • Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided.
  • the desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and /or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1- 39; all of which are incorporated by reference herein).
  • Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided.
  • organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s).
  • Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al, 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al, 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al, 1988, Nature 336: 348-352; U.S. Patent Nos.
  • the present invention also provides for soluble forms of such protein.
  • the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed.
  • the intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.
  • Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.
  • Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention.
  • a "species homologue” is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide.
  • polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.
  • species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus oedipus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canisfamiliaris, Oryctolagus cuniculus, Bos taurus, Ovis aries, Sus scrofa, and Equus caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species
  • allelic variants of the disclosed polynucleotides or proteins that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides.
  • allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.
  • the invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
  • the present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein.
  • stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.
  • the hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides.
  • the hybrid length is assumed to be that of the hybridizing polynucleotide.
  • the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.
  • SSPE lxSSPE is 0.15M NaCl, lOmM NaH 2 P0 4 , and 1.25mM EDTA, pH 7.4
  • SSC 0.15M NaCl and 15mM sodium citrate
  • each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • the isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in
  • operably linked means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
  • Mammalian host cells include, for example, monkey COS cells, Chinese Hamster
  • Ovary (CHO) cells human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
  • yeast eukaryotes
  • prokaryotes such as bacteria.
  • yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins.
  • Potentially suitable bacterial strains include Escherichia coli, Bacillus subt ⁇ lis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
  • the protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
  • suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
  • Materials and methods for baculovirus /insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference.
  • an insect cell capable of expressing a polynucleotide of the present invention is "transformed.”
  • the protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein.
  • the resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography.
  • the purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
  • the protein of the invention may also be expressed in a form which will facilitate purification.
  • it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively.
  • MBP maltose binding protein
  • GST glutathione-S-transferase
  • TRX thioredoxin
  • Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively.
  • the protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope.
  • One such epitope (“Flag") is commercially available from Kod
  • RP- HPLC reverse-phase high performance liquid chromatography
  • hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other aliphatic groups
  • Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein.
  • the protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein.”
  • the protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
  • the protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art.
  • the synthetically-constructed protein sequences by virtue of sharing primary, secondary or tertiary structural and /or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
  • the proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques.
  • Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence.
  • one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule.
  • Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No.4,518,584).
  • such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.
  • polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below.
  • Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
  • the polynucleotides provided by the present invention can be used by the research community for various purposes.
  • the polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques;
  • the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction)
  • the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al, 1993, Cell 75: 791-803 and in Rossi et al., 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.
  • the proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high- throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands.
  • the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction)
  • the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
  • Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate.
  • the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules.
  • the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured. Cytokine and Cell Proliferation /Differentiation Activity
  • a protein of the present invention may exhibit cytokine, cell.proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations.
  • cytokine cytokine
  • cell.proliferation either inducing or inhibiting
  • cell differentiation either inducing or inhibiting
  • the activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol.
  • Assays for cytokine production and /or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon ⁇ , Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.
  • Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current
  • Assays for T-cell clone responses to antigens include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci.
  • a protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein.
  • a protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and /or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.
  • SOD severe combined immunodeficiency
  • These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders.
  • infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis.
  • a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
  • Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease.
  • a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems.
  • Other conditions, in which immune suppression is desired may also be treatable using a protein of the present invention.
  • T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both.
  • Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent.
  • Tolerance which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
  • Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD).
  • B lymphocyte antigen functions such as , for example, B7
  • GVHD graft-versus-host disease
  • blockage of T cell function should result in reduced tissue destruction in tissue transplantation.
  • rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant.
  • a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen ⁇ e.g., B7- 1, B7-3) or blocking antibody
  • a B7 lymphocyte antigen such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen ⁇ e.g., B7- 1, B7-3) or blocking antibody
  • Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant.
  • the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject.
  • Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents.
  • To achieve sufficient immunosuppression or tolerance in a subject it may also be necessary to block the function of a combination of B lymphocyte antigens.
  • the efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.
  • Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al, Science 257:789-792 (1992) and Turka et al, Proc. Natl. Acad. Sci USA, 39:11102-11105 (1992).
  • murine models of GVHD see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.
  • Blocking antigen function may also be therapeutically useful for treating autoimmune diseases.
  • Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases.
  • Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
  • Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process.
  • blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease.
  • the efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL /Ipr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
  • Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.
  • anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen- pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient.
  • Another method of enhancing anti- viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient.
  • the infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
  • up regulation or enhancement of antigen function may be useful in the induction of tumor immunity.
  • Tumor cells e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma
  • a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.
  • tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and /or B7-3-like activity.
  • the transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell.
  • gene therapy techniques can be used to target a tumor cell for transfection in vivo.
  • tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II a chain protein and an MHC class II ⁇ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II a chain protein and an MHC class II ⁇ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity.
  • a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
  • T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
  • MLR Mixed lymphocyte reaction
  • Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol.
  • lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al, Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al, Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.
  • Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.
  • a protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g.
  • erythroid progenitor cells in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and /or erythroid cells; in supporting the growth and proliferation of m eloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above- mentioned hematopoietic cells and therefore find therapeutic utility in various
  • Assays for embryonic stem cell differentiation include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood
  • Assays for stem cell survival and differentiation include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A.
  • a protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and /or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
  • a protein of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals.
  • Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
  • a protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells.
  • a protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and /or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
  • tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation.
  • a protein of the present invention which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals.
  • Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue.
  • compositions of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments.
  • the compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair.
  • the compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects.
  • the compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.
  • the protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyofrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
  • Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like. It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.
  • organs including, for example, pancreas, liver, intestine, kidney, skin, endothelium
  • muscle smooth, skeletal or cardiac
  • vascular including vascular endothelium
  • a protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
  • a protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/ 16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).
  • Assays for wound healing activity include, without limitation, those described in:
  • a protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH).
  • FSH follicle stimulating hormone
  • a protein of the present invention alone or in heterodimers with a member of the inhibin ⁇ family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals.
  • the protein of the invention may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885.
  • a protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
  • a protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.
  • Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action.
  • Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
  • a protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population.
  • the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for chemotactic activity consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population.
  • Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest.
  • a protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes.
  • a protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis
  • a protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions.
  • receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses).
  • Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
  • a protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.
  • Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-lnterscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med.
  • Anti-Inflammatory Activity Proteins of the present invention may also exhibit anti-inflammatory activity.
  • the anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response.
  • Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hvpersensitivity to an antigenic substance or material.
  • infection such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)
  • ischemia-reperfusion injury such as endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease
  • Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.
  • the cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule.
  • the cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.
  • E-cadherin one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage- independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types.
  • proteins of the present invention with cadherin activity can be used to treat cancer.
  • Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.
  • Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body.
  • Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
  • proteins of the present invention with cadherin activity can be used to generate antibodies recognizing and binding to cadherins.
  • Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere.
  • Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.
  • Fragments of proteins of the present invention with cadherin activity can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
  • Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.
  • a protein of the invention may exhibit other anti-tumor activities.
  • a protein may inhibit tumor growth directly or indirectly (such as, for example, via
  • a protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
  • a protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting
  • bodily characteristics including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperpro
  • a protein of the present invention may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
  • pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.
  • the pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin.
  • the pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment.
  • protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
  • a protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins.
  • pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
  • the pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens.
  • the protein and /or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes.
  • B lymphocytes will respond to antigen through their surface immunoglobulin receptor.
  • T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins.
  • TCR T cell receptor
  • MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes.
  • the antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells.
  • the pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution.
  • amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution.
  • Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like.
  • the term "therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
  • a meaningful patient benefit i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
  • the term refers to that ingredient alone.
  • a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated.
  • Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors.
  • protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
  • Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.
  • protein of the present invention When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir.
  • the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant.
  • the tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
  • a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added.
  • the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.
  • the pharmaceutical composition When administered in liquid form, contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
  • protein of the present invention When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
  • parenterally acceptable protein solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
  • a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride
  • the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
  • the amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further.
  • compositions used to practice the method of the present invention should contain about 0.01 ⁇ g to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 ⁇ g to about 1 mg) of protein of the present invention per kg body weight.
  • the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration.
  • Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen.
  • the peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH).
  • KLH keyhole limpet hemocyanin
  • Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein.
  • Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved.
  • neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
  • the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device.
  • the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form.
  • the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage.
  • Topical administration may be suitable for wound healing and tissue repair.
  • Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention.
  • the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
  • a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
  • Such matrices may be formed of materials presently in use for other implanted medical applications. The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation.
  • Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides.
  • Other potential materials are biodegradable and biologically well- defined, such as bone or dermal collagen.
  • Further matrices are comprised of pure proteins or extracellular matrix components.
  • Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics.
  • Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate.
  • the bioceramics may be altered in composition, such as in calcium- aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.
  • a sequestering agent such as carboxymethyl cellulose or autologous blood clot
  • a preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC).
  • sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol).
  • the amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
  • proteins of the invention may be combined with other agents beneficial to the treatment of the bone and /or cartilage defect, wound, or tissue in question.
  • agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- ⁇ and
  • TGF- ⁇ TGF- ⁇
  • IGF insulin-like growth factor
  • the therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.
  • the dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors.
  • the dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition.
  • IGF I insulin like growth factor I
  • the addition of other known growth factors, such as IGF I may also effect the dosage.
  • Progress can be monitored by periodic assessment of tissue/bone growth and /or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
  • Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
  • Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
  • CAGCAGCCTC CACAGGGGGT TAAGTARAGA ACCATCCAAG CATCACAGAG TGTCATCCAG 300
  • CTGAGCATAA ATAACTTGTT CTATATCTGG CTCCAAGTCC ATTTCTGTTC TGTCTTGGAG 540
  • ACTTACACTA AATAATAATG TTGTTTTGAA TGGGGTTGTG GGTAATTCCT ATATTCTTCT 900
  • GCTTAAACAT TACTATGGCT TGGAATCTCA TTTCAAAAAA TCTTTAAAAT GGGGACAAGA 1020
  • AAAAAAAAAA AAAAA 2355 ( 2 ) INFORMATION FOR SEQ ID NO : 2 :
  • CCTTCACTGT CAGCAGCTCG GTGACATTCC AGGTTACCCG GGAGGATGAT GGGGCGAGCA 720
  • CTTTCCTCAA CAAGAGTGAC AGTGGCACCT ACGGCTGCAC AGCCACCAGC AACATGGGCA 1020
  • MOLECULE TYPE protein
  • Gin Arg lie Glu Val Leu Tyr Thr Pro Thr Ala Met lie Arg Pro Asp 225 230 235 240
  • Gly Ser Asp Asp Ala Pro Asp Ala Asp Thr Ala lie asn Ala Glu ' 370 375 380
  • CAGCTCACTG CAGCCTTGAA CTCGTGGGCT CAAGCCATCC TCCTGTGTCA GCCTCCCCAG 780
  • AAAA 2764 INFORMATION FOR SEQ ID NO: 6:
  • Thr Lys Leu Thr lie Thr Gin Ala Val Thr Thr Thr Thr Thr Trp Thr 145 150 155 160
  • AAAGACAGAG AAGAGCTGTC CAGCAGGGAG AATAGGGCCC TGAAGGAAGG GCACCGCCAA 540
  • AGTATATATA TATTTTTAAC TTTTCACTTG ATTCTTCTCT GTAGCCAAGG TTGAGAACCG 2820
  • AAAAATACAC TGGACCAGAT AGTAGACTGG TCCCTTGATC AGAAGCATCA GCACATCAGC 3000
  • GAACACCGTG AACCTCAGTT ATTGCTAGAT ATTAAAGAAG AAATTGAAGA TGAAGAAAAG 420
  • TGT 483 INFORMATION FOR SEQ ID NO: 12:
  • MOLECULE TYPE protein
  • Lys Val Gin lie Ser Tyr Trp Met Lys Leu Leu Leu Leu Leu Lys Tyr Leu 20 25 30
  • Thr Ser Arg lie Val Gly Thr Thr Ala Tyr Met Ala Pro Glu Ala Leu 50 55 60
  • Leu Leu Glu lie lie Thr Gly Leu Pro Ala Val Asp Glu His Arg Glu 85 90 95
  • TTAGTGGACT TACCTTCAAC CAATGGACAG AGCCCTGGCA AAGCCATTGA GAACTTGATT 480
  • CTGTATAAAA AATAAAATAA TGAAAGCAAC CTAAAAATAG GATGCACCAA TTAAAAAAAA 2640

Abstract

Polynucleotides and the proteins encoded thereby are disclosed.

Description

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of application Ser. No. 60/XXX,XXX
(converted to a provisional application from non-provisional application Ser. No. 08/823,330), filed March 28, 1997, which is incorporated by reference herein.
FIELD OF THE INVENΗON The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
BACKGROUND OF THE INVENTION Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA /amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA /amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed. SUMMARY OF THE INVENTION In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 170 to nucleotide 322;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 218 to nucleotide 322; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:l from nucleotide 1814 to nucleotide 2355;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379; (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 20 to amino acid 29 of SEQ ID NO:2;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:l from nucleotide 170 to nucleotide 322; the nucleotide sequence of SEQ ID NO:l from nucleotide 218 to nucleotide 322; the nucleotide sequence of SEQ ID NO:l from nucleotide 1814 to nucleotide 2355; the nucleotide sequence of the full-length protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:l.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2;
(b) fragments of the amino acid sequence of SEQ ID NO:2 comprising the amino acid sequence from amino acid 20 to amino acid 29 of SEQ ID NO:2; and
(c) the amino acid sequence encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 102 to nucleotide 1295;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 162 to nucleotide 1295; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:3 from nucleotide 804 to nucleotide 1184;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone crll62_25 deposited under accession number ATCC 98379; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone crll62_25 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4; (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO:4;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:3 from nucleotide 102 to nucleotide 1295; the nucleotide sequence ot SEQ ID NO:3 from nucleotide 162 to nucleotide 1295; the nucleotide sequence of SEQ ID NO:3 from nucleotide 804 to nucleotide 1184; the nucleotide sequence of the full-length protein coding sequence of clone crll62_25 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone crl 162_25 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 236 to amino acid 361.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:4; (b) the amino acid sequence of SEQ ID NO:4 from amino acid 236 to amino acid 361;
(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO:4; and (d) the amino acid sequence encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 236 to amino acid 361. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 351 to nucleotide 842;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 687 to nucleotide 842;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 689; (e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ
ID NO:6;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 351 to nucleotide 842; the nucleotide sequence of SEQ ID NO:5 from nucleotide 687 to nucleotide 842; the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 689; the nucleotide sequence of the full-length protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 113.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:6; (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 113;
(c) fragments of the amino acid sequence of SEQ ID NO:6 comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:6; and (d) the amino acid sequence encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 113.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:7 from nucleotide 2205 to nucleotide 2882;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 2262 to nucleotide 2882;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 2494 to nucleotide 3120;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone di39_9 deposited under accession number ATCC 98379;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone di39_9 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 108 to amino acid 117 of
SEQ ID NO:8;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:7 from nucleotide 2205 to nucleotide 2882; the nucleotide sequence of SEQ ID NO:7 from nucleotide 2262 to nucleotide 2882; the nucleotide sequence of SEQ ID NO:7 from nucleotide 2494 to nucleotide 3120; the nucleotide sequence of the full-length protein coding sequence of clone di39_9 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone di39_9 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:8; (b) fragments of the amino acid sequence of SEQ ID NO: 8 comprising the amino acid sequence from amino acid 108 to amino acid 117 of SEQ ID NO:8; and
(c) the amino acid sequence encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 40 to nucleotide 1503;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 863 to nucleotide 1377; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of
SEQ ID NO:10;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 40 to nucleotide 1503; the nucleotide sequence of SEQ ID NO:9 from nucleotide 863 to nucleotide 1377; the nucleotide sequence of the full-length protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10 from amino acid 277 to amino acid 446. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:10;
(b) the amino acid sequence of SEQ ID NO:10 from amino acid 277 to amino acid 446;
(c) fragments of the amino acid sequence of SEQ ID NO:10 comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:10; and
(d) the amino acid sequence encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10 or the amino acid sequence of SEQ ID NO:10 from amino acid 277 to amino acid 446.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:ll;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 11 from nucleotide 85 to nucleotide 450;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 11 from nucleotide 217 to nucleotide 450; (d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone eh61_l deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone eh61_l deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ
ID NO:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:ll from nucleotide 85 to nucleotide 450; the nucleotide sequence of SEQ ID NO:ll from nucleotide 217 to nucleotide 450; the nucleotide sequence of the full-length protein coding sequence of clone eh61_l deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone eh61_l deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12 from amino acid 9 to amino acid 94.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO.11 or SEQ ID NO:13. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 12;
(b) the amino acid sequence of SEQ ID NO:12 from amino acid 9 to amino acid 94;
(c) fragments of the amino acid sequence of SEQ ID NO:12 comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO: 12; and (d) the amino acid sequence encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence of SEQ ID NO:12 from amino acid 9 to amino acid 94.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:14 from nucleotide 900 to nucleotide 1073;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14 from nucleotide 544 to nucleotide 1022;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone fg265_l deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fg265_l deposited under accession number
ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 15 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:15; (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:14 from nucleotide 900 to nucleotide 1073; the nucleotide sequence of SEQ ID NO:14 from nucleotide 544 to nucleotide 1022; the nucleotide sequence of the full-length protein coding sequence of clone fg265_l deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone fg265_l deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15 from amino acid 1 to amino acid 41.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:14.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:15; (b) the amino acid sequence of SEQ ID NO:15 from amino acid 1 to amino acid 41;
(c) fragments of the amino acid sequence of SEQ ID NO: 15 comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO: 15; and (d) the amino acid sequence encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:15 or the amino acid sequence of SEQ ID NO:15 from amino acid 1 to amino acid 41. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 119 to nucleotide 2440;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 200 to nucleotide 2440; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO: 16 from nucleotide 460 to nucleotide 1153;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379; (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:17;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:17 having biological activity, the fragment comprising the amino acid sequence from amino acid 382 to amino acid 391 of SEQ ID NO:17;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:16 from nucleotide 119 to nucleotide 2440; the nucleotide sequence of SEQ ID NO:16 from nucleotide 200 to nucleotide 2440; the nucleotide sequence of SEQ ID NO:16 from nucleotide 460 to nucleotide 1153; the nucleotide sequence of the full-length protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:17 from amino acid 115 to amino acid 345.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:16.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 17;
(b) the amino acid sequence of SEQ ID NO: 17 from amino acid 115 to amino acid 345; (c) fragments of the amino acid sequence of SEQ ID NO: 17 comprising the amino acid sequence from amino acid 382 to amino acid 391 of SEQ ID NO:17; and
(d) the amino acid sequence encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 17 or the amino acid sequence of SEQ ID NO:17 from amino acid 115 to amino acid 345.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:18;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 1187 to nucleotide 1804;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 674 to nucleotide 1014;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone fy243_8 deposited under accession number ATCC 98379; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fy243_8 deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:19 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:19;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:18 from nucleotide 1187 to nucleotide 1804; the nucleotide sequence of SEQ ID NO:18 from nucleotide 674 to nucleotide 1014; the nucleotide sequence of the full-length protein coding sequence of clone fy243_8 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone fy243_8 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19 from amino acid 21 to amino acid 69.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:18. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:19; (b) the amino acid sequence of SEQ ID NO:19 from amino acid 21 to amino acid 69;
(c) fragments of the amino acid sequence of SEQ ID NO:19 comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:19; and (d) the amino acid sequence encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:19 or the amino acid sequence of SEQ ID NO:19 from amino acid 21 to amino acid 69. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 99 to nucleotide 536;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 1 to nucleotide 370;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:21; (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 99 to nucleotide 536; the nucleotide sequence of SEQ ID NO:20 from nucleotide 1 to nucleotide 370; the nucleotide sequence of the full-length protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379; or the nucleotide sequence of a mature protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21 from amino acid 1 to amino acid
90.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:20.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:21;
(b) the amino acid sequence of SEQ ID NO:21 from amino acid 1 to amino acid 90; (c) fragments of the amino acid sequence of SEQ ID NO:21 comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:21; and
(d) the amino acid sequence encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:21 or the .amino acid sequence of SEQ ID NO:21 from amino acid 1 to amino acid 90.
In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein. Processes are also provided for producing a protein, which comprise:
(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
(b) purifying the protein from the culture.
The protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.
Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention. Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1 A and IB are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.
DETAILED DESCRIPTION ISOLATED PROTEINS AND POLYNUCLEOTIDES
Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
Clone "b!209 10" A polynucleotide of the present invention has been identified as clone "bl209_10". bl209_10 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bl209_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bl209_10 protein").
The nucleotide sequence of bl209_10 as presently determined is reported in SEQ ID NO:l. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bl209_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 4 to 16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17, or are a transmembrane domain.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone bl209_10 should be approximately 2400 bp. The nucleotide sequence disclosed herein for bl209_10 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bl209_10 demonstrated at least some similarity with sequences identified as AA522436 (ng30g05.sl NCI_CGAP_ Co3 Homo sapiens cDNA clone IMAGE 936344), L06147 (Human (clone SY11) golgin-95 mRNA, complete eds), N29620 (yw67d06.sl Homo sapiens cDNA clone 257291 3'), N41622 (yw67d06.rl Homo sapiens cDNA clone 257291 5'), N80172 (za65g07.sl Homo sapiens cDNA clone 297468 3'), and U35022 (Rattus norvegicus cis-Golgi matrix protein GM130 mRNA, complete eds). The predicted amino acid sequence disclosed herein for bl209_10 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bl209_10 protein demonstrated at least some similarity to sequences identified as M34651 (immediate-early protein [Suid herpesvirus]). Based upon sequence similarity, bl209_10 proteins and each similar protein or peptide may share at least some activity. [The TopPredll computer program predicts N potential transmembrane domains within the bl209_10 protein sequence, one around amino acid X and another around amino acid Y of SEQ ID NO:2.] [The nucleotide /amino add sequence of bl209_10 indicates that it may contain an Alu repetitive element.]
Clone "crl 162 25" A polynucleotide of the present invention has been identified as clone "crll62_25".
Secreted cDNA clones were first isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.
5,536,637), or were identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. These cDNA clones were then used to isolate crll62_25, a full-length human cDNA clone which includes the entire coding sequence of a secreted protein (also referred to herein as
"crll62_25 protein"), from a human fetal brain cDNA lbrary.
The nucleotide sequence of crll62_25 as presently determined is reported in SEQ
ID NO:3. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the crll62_25 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 8 to 20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21, or are a transmembrane domain.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone crll62_25 should be approximately 3700 bp.
The nucleotide sequence disclosed herein for crll62_25 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/ BLASTX and FASTA search protocols. crll62_25 demonstrated at least some similarity with sequences identified as H14720 (ym24b05.rl Homo sapiens cDNA clone 48883 5'), H15268 (ym30dll.rl Homo sapiens cDNA clone 499045'), and N45514 (yy59g07.rl Homo sapiens cDNA clone 2778845'). The predicted amino acid sequence disclosed herein for crll62_25 was searched against the GenPept, GeneSeq, and SwissProt amino acid sequence databases using the BLASTX search protocol. The predicted crll62_25 protein demonstrated at least some similarity to sequences identified as D12612 (poliovirus receptor gene [Cercopithecus aethiops]), D26156 (hSNF2b; transcriptional activator [Homo sapiens], L12589 (B-lymphocyte activation antigen 7 [Mus museums]), P51532 (POSSIBLE GLOBAL TRANSCRIPTION ACTIVATOR SNF2L3 ( OR SNF2-BETA OR BRG-1) [Homo sapiens]), R07130 (H20B receptor), U29175 (transcriptional activator (BRG1)) [Homo sapiens]), X57516 (poliovirus receptor alpha [Homo sapiens]), X60958 (B lymphocyte activation antigen [Mus musculus]), X64116 (poliovirus receptor alpha [Homo sapiens]), and X68274 (TAG-l/axonin-1 [Homo sapiens]). Based upon sequence similarity, crll62_25 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts an additional potential transmembrane domain at the carboxy terminus of the crll62_25 protein sequence, centered around amino acid 342 of SEQ ID NO:4.
Clone "dh40 3"
A polynucleotide of the present invention has been identified as clone "dh40_3". dh40_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dh40_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dh40_3 protein").
The nucleotide sequence of dh40_3 as presently determined is reported in SEQ ID NO:5. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dh40_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 100 to 112 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 113, or are a transmembrane domain.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone dh40_3 should be approximately 3000 bp. The nucleotide sequence disclosed herein for dh40_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dh40_3 demonstrated at least some similarity with sequences identified as AG005063 (Homo sapiens genomic DNA, 21q region, clone T1957SpNll), Z67586 (H.sapiens DNA segment containing (CA) repeat), and Z74023 (Human DNA sequence from cosmid LUC A3 on chromosome 3p21.3. contains ESTs). Based upon sequence similarity, dh40_3 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts an additional potential transmembrane domain within the dh40_3 protein sequence at the extreme carboxy terminus of SEQ ID NO:6.
Clone "di39 9"
A polynucleotide of the present invention has been identified as clone "di39_9". di39_9 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. di39_9 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "di39_9 protein"). The nucleotide sequence of di39_9 as presently determined is reported in SEQ ID
NO:7. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the di39_9 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 7 to 19 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone di39_9 should be approximately 3000 bp.
The nucleotide sequence disclosed herein for di39_9 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. di39_9 demonstrated at least some similarity with sequences identified as AA249116 (hfe0042.seq.F Human fetal heart, Lambda ZAP Express Homo sapiens cDNA 5'), AA598667 (ae40a05.sl Gessler Wilms tumor Homo sapiens cDNA clone 8982563'), N53166 (yv56ell.sl Homo sapiens cDNA clone 2467643'), N80292 (za96h08.sl Homo sapiens cDNA clone 3004473'), T86182 (JTV1 coding sequence), U24169 (Human JTV-1 OTV-1) mRNA, complete eds), U38964 (Human PMS2 related (hPMSR2) gene, complete eds), and W24630 (zb62g08.rl Soares fetal lung NbHL19W Homo sapiens cDNA clone 308222 5'). The predicted amino acid sequence disclosed herein for di39_9 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted di39_9 protein demonstrated at least some similarity to sequences identified as U24169 (JTV-1 [Homo sapiens]), U38964 (hPMSR2 [Homo sapiens]), and W25776 (JTV1 protein). The positioning of the regions of similarity to hPMSR2 and JTV-1 relative to each other in the di39_9 sequence is quite similar to that of the JTV-1 and PMS2 sequences in the human genome. Based upon sequence similarity, di39_9 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts two additional potential transmembrane domains within the di39_9 protein sequence, one centered around amino acid 160 and another around amino acid 200 of SEQ ID NO:8.
Clone "dt674 2"
A polynucleotide of the present invention has been identified as clone "dt674_2". dt674_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dt674_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dt674_2 protein").
The nucleotide sequence of dt674_2 as presently determined is reported in SEQ ID NO:9. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dt674_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone dt674_2 should be approximately 3500 bp.
The nucleotide sequence disclosed herein for dt674_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
FASTA search protocols. dt674_2 demonstrated at least some similarity with sequences identified as T06736 (EST04625 Homo sapiens cDNA clone HFBDX78). The predicted amino acid sequence disclosed herein for dt674_2 was searched against the GenPept and GeneSeq amino add sequence databases using the BLASTX search protocol. The predicted dt674_2 protein demonstrated at least some similarity to sequences identified as Z72807 (ORF YGR023w [Saccharomyces cerevisiae]). Based upon.sequence similarity, dt674_2 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dt674_2 indicates that it may contain at least one copy of one or more repetitive elements.
Clone "eh61 1"
A polynucleotide of the present invention has been identified as clone "eh61_l". eh61_l was isolated from a human adult blood (peripheral blood mononuclear cells treated with granulocyte-colony stimulating factor in vivo) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. eh61_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "eh61_l protein").
The nucleotide sequence of the 5' portion of eh61_l as presently determined is reported in SEQ ID NO:ll. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:12. The predicted amino acid sequence of the eh61_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 32 to 44 are a predicted leader /signal sequence, with the predicted mature amino acid sequence beginning at amino acid 45, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of eh61_l, including the polyA tail, is reported in SEQ ID NO: 13.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone eh61_l should be approximately 2200 bp.
The nucleotide sequence disclosed herein for eh61_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. eh61_l demonstrated at least some similarity with sequences identified as AA114131 (zn75g05.sl Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 564056 3' similar to contains Alu repetitive element;contains element
TAR1 repetitive element), H53674 (yu38e03.rl Homo sapiens cDNA clone 236092 5'), L24093 (Gorilla gorilla ADP-ribosyltransferase (NAD+) pseudogene, repeat region), N38129 (19356 Arabidopsis thaliana cDNA clone 219I8T7), T04321 (368 Arabidopsis thaliana cDNA clone), U45981 (Schizosaccharomyces pombe Ste20-related protein kinase (shk2) gene, complete eds), and X97774 (A.thaliana mRNA for light represssible receptor protein kinase). The predicted amino acid sequence disclosed herein for eh61_l was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted eh61_l protein demonstrated at least some similarity to sequences identified as D10152 (protein tyrosine-serine-threonine kinase [Arabidopsis thaliana]), L24521 (transformation-related protein [Homo sapiens]), and L76191 (interleukin-1 receptor-associated kinase [Homo sapiens]). Based upon sequence similarity, eh61_l proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of eh61_l indicates that it may contain an Alu repetitive element.
Clone "fg265 1"
A polynucleotide of the present invention has been identified as clone "fg265_l". fg265_l was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fg265_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fg265_l protein"). The nucleotide sequence of fg265_l as presently determined is reported in SEQ ID
NO:14. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fg265_l protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:15.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone fg265_l should be approximately 3100 bp.
The nucleotide sequence disclosed herein for fg265_l was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols, f g265_l demonstrated at least some similarity with sequences identified as AA076592 (zm91hl0.rl Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 5453475'), AA482600 (zt34al2.sl Soares ovary tumor NbHOT Homo sapiens cDNA), N23393 (yx83dl2.sl Homo sapiens cDNA clone 268343 3'), R10011 (yf34g05.rl Homo sapiens cDNA clone 128792 5'), R41186 (yf84c08.sl Homo sapiens cDNA clone 293133'), and W87844 (zh68a05.rl Soares fetal liver spleen 1NFLS SI Homo sapiens cDNA clone 417200 5'). Based upon sequence similarity, fg265_l proteins and each similar protein or peptide may share at least some activity.
Clone "fp273 10" A polynucleotide of the present invention has been identified as clone "fp273_10". fp273_10 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fp273_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fp273_10 protein").
The nucleotide sequence of fp273_10 as presently determined is reported in SEQ ID NO:16. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fp273_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:17. Amino acids 15 to 27 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28, or are a transmembrane domain.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone fp273_10 should be approximately 3800 bp. The nucleotide sequence disclosed herein for fp273_10 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fp273_10 demonstrated at least some similarity with sequences identified as R16387 (yf91g01.rl Homo sapiens cDNA clone 29825 5'), R17806 (yg09b06.rl Homo sapiens cDNA clone 317635'), and T65784 (ycllflO.sl Homo sapiens cDNA clone 80395 3' similar to contains LI repetitive element). Based upon sequence similarity, fp273_10 proteins and each similar protein or peptide may share at least some activity. The TopPredll computer program predicts four additional potential transmembrane domains within the fp273_10 protein sequence, centered around amino acids 140, 530, 560, and 720 of SEQ ID NO:17, respectively. At amino acid 449 of SEQ ID NO:17, the fp273_10 protein has a C-5 cytosine-specific DNA methylase motif.
Clone "fv243 8"
A polynucleotide of the present invention has been identified as clone "fy243_8". fy243_8 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fy243_8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fy243_8 protein").
The nucleotide sequence of fy243_8 as presently determined is reported in SEQ ID NO:18. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fy243_8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:19. Additional open reading frames for fy243_8 are predicted at basepairs 297 to 635, at basepairs 826 to 1014, and at basepairs 1102 to 1248 of SEQ ID NO:18; the predicted amino acid sequences corresponding to the foregoing nucleotide sequences are reported in SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34, respectively. The open reading frame for SEQ ID NO:19 could be joined to those for SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34 if the intervening nucleotide sequences of SEQ ID NO:18 were removed.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone fy243_8 should be approximately 2200 bp.
The nucleotide sequence disclosed herein for fy243_8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fy243_8 demonstrated at least some similarity with sequences identified as AA121177 (zl88h03.sl Stratagene colon (#937204) Homo sapiens cDNA clone 511733 3'), AA121218 (zl88h03.rl Stratagene colon (#937204) Homo sapiens cDNA clone 511733 5' similar to WP F44B9.5 CE00552), AA126582 (zn86gl2.sl Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565126 3'), R73372 (yll0g08.rl Homo sapiens cDNA clone 157886 5' similar to SP F44B9.5 CE00552), T27033 (NIBT173E09R Infant brain, LLNL array of Dr. M. Soares 1NIB Homo sapiens cDNA clone LLAB173E09 5'end), and U41736 (Mus musculus ancient ubiquitous 46 kDa protein AUP1 precursor (Aupl) mRNA, complete eds). The predicted amino acid sequence disclosed herein for fy243_8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fy243_8 protein demonstrated at least some similarity to sequences identified as U41736 (ancient ubiquitous 46 kDa protein AUP46 precursor [Mus musculus]). Based upon sequence similarity, fy243_8 proteins and each similar protein or peptide may share at least some activity. Clone "ea205 4"
A polynucleotide of the present invention has been identified as clone "ga205_4". ga205_4 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ga205_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ga205_4 protein").
The nucleotide sequence of ga205_4 as presently determined is reported in SEQ ID NO:20. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ga205_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:21.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone ga205_4 should be approximately 1000 bp. The nucleotide sequence disclosed herein for ga205_4 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ga205_4 demonstrated at least some similarity with sequences identified as AA075247 (zm86e01.rl Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 544824 5'), AA081273 (zn33el2.sl Stratagene endothelial cell 937223 Homo sapiens cDNA clone 5492623'), AA203476 (zx55e01.rl Soares fetal liver spleen INFLS SI Homo sapiens cDNA clone 446424 5' similar to contains element LI repetitive element), T21011 (Human gene signature HUMGS02293), and U73030 (Rattus norvegicus pituitary tumor-specific transforming factor mRNA, complete eds). The predicted amino acid sequence disclosed herein for ga205_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ga205_4 protein demonstrated at least some similarity to sequences identified as U73030 (PTTG gene product [Rattus norvegicus]). Based upon sequence similarity, ga205_4 proteins and each similar protein or peptide may share at least some activity.
Deposit of Clones
Clones bl209_10, crll62_25, dh40_3, di39_9, dt674_2, eh61_l, fg265_l, fp273_10, fy243_8, and ga205_4 were deposited on March 28, 1997 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98379, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806. Each clone has been transfected into separate bacterial cells (E. coli) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/Notl digestion (5' site, EcoRI; 3' site, Notl) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1. The pED6dpc2 vector ("pED6") was derived from pEDόdpcl by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res. 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al., 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the Ml 3 origin of replication in the Clal site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and Notl. However, Notl will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited. Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
Clone Probe Sequence bl209_10 SEQ ID NO:22 crll62_25 SEQ ID NO:23 dh40_3 SEQ ID NO:24 di39_9 SEQ ID NO:25 dt674_2 SEQ ID NO:26 eh61_l SEQ ID NO:27 fg265_l SEQ ID NO:28 fp273_10 SEQ ID NO:29. fy243_8 SEQ ID NO:30 ga205_4 SEQ ID NO:31
In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1- dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N- diisopropyl)-phosphoramadite) (Glen Research, cat. no. 10-1953)).
The design of the oligonucleotide probe should preferably follow these parameters:
(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any; (b) It should be designed to have a Tm of approx. 80 ° C (assuming 2° for each
A or T and 4 degrees for each G or C).
The oligonucleotide should preferably be labeled with g-32P ATP (specific activity 6000
Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them. The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 μg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.
The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.
Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al, Bio /Technology 10, 773-778 (1992) and in R.S. McDowell, et al, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.
The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form. The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and /or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.
Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and /or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1- 39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 Bl, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al, 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al, 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al, 1988, Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059;.5,631,153; 5,614, 396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.
Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus oedipus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canisfamiliaris, Oryctolagus cuniculus, Bos taurus, Ovis aries, Sus scrofa, and Equus caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuanez, 1988, Ann. Rev. Genet. 22: 323-351; O'Brien et al, 1993, Nature Genetics 3:103-112; Johansson et al, 1995, Genomics 25: 682-690; Lyons et al, 1997, Nature Genetics 15: 47-56; O'Brien et al, 1997, Trends in Genetics 13(10): 393-399; Carver and Stubbs, 1997, Genome Research 7:1123-1137; all of which are incorporated by reference herein).
The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.
The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.
Figure imgf000038_0001
*: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity. *: SSPE (lxSSPE is 0.15M NaCl, lOmM NaH2P04, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (lxSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.
*TB - TR: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, Tm(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, Tm(°C) = 81.5 + 16.6(log10[Na+]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na+] for lxSSC = 0.165 M).
Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.
Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in
Kaufman et al, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster
Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtϊlis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus /insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."
The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).
Finally, one or more reverse-phase high performance liquid chromatography (RP- HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."
The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and /or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies. The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No.4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.
Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.
USES AND BIOLOGICAL ACTIVITY The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
Research Uses and Utilities
The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al, 1993, Cell 75: 791-803 and in Rossi et al., 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction. The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high- throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products. Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.
Nutritional Uses
Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured. Cytokine and Cell Proliferation /Differentiation Activity
A protein of the present invention may exhibit cytokine, cell.proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J.
Immunol. 152: 1756-1761, 1994.
Assays for cytokine production and /or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ, Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.
Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current
Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.
Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al, J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.
Immune Stimulating or Suppressing Activity A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and /or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer. Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.
Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen {e.g., B7- 1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens. The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al, Science 257:789-792 (1992) and Turka et al, Proc. Natl. Acad. Sci USA, 39:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease. Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL /Ipr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.
Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen- pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti- viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and /or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.
The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β2 microglobulin protein or an MHC class II a chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1- 3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al, J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al, J. Immunol. 135:1564-1572, 1985; Takai et al, J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al, J. Immunol. 153:3079-3092, 1994.
Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Pubhshing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992. Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al, Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.
Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al, Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al, Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.
Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.
Hematopoiesis Regulating Activity
A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and /or erythroid cells; in supporting the growth and proliferation of m eloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above- mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy. The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.
Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood
81:2903-2915, 1993.
Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.
Tissue Growth Activity
A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and /or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and /or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.
The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyofrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like. It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.
A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/ 16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ). Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).
Activin/ Inhibin Activity
A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
Chemotactic /Chemokinetic Activity
A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.
Hemostatic and Thrombolytic Activity
A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis
Res.45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.
Receptor /Ligand Activity A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.
The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-lnterscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.
Anti-Inflammatory Activity Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hvpersensitivity to an antigenic substance or material.
Cadherin/Tumor Invasion Suppressor Activity
Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.
The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.
E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage- independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression. Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody. Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.
Tumor Inhibition Activity
In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via
ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
Other Activities
A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting
(suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.
ADMINISTRATION AND DOSING
A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and /or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No.4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No.4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference. As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.
When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride
Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein of the present invention per kg body weight.
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration.
Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and /or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications. The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well- defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium- aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix. A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and /or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-α and
TGF-β), and insulin-like growth factor (IGF).
The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and /or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
Patent and literature references cited herein are incorporated by reference as if fully set forth.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Jacobs, Kenneth McCoy, John M. LaVallie, Edward R. Racie, Lisa A. Merberg, David Treacy, Maurice Spaulding, Vi ki Agostino, Michael J.
(ii) TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
(iii) NUMBER OF SEQUENCES: 34
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genetics Institute, Inc.
(B) STREET: 87 CambridgePark Drive
(C) CITY: Cambridge
(D) STATE: MA
(E) COUNTRY: U.S.A.
(F) ZIP: 02140
(V) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Sprunger, Suzanne A.
(B) REGISTRATION NUMBER: 41,323
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 498-8284
(B) TELEFAX: (617) 876-5851
(2) INFORMATION FOR SEQ ID NO : 1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2355 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 :
CGCTTTTTTT TTTTTTTTTT TTCAGAAGGA GGAAGCTCAT TATGTTTGGA TCACCCACAG 60
CTATAGATTC TAAAAATATT TTGGCTTTTT TTGAGGTGCT TTAGTAAAAT ATAACCCCAA 120
ATGATTCACT TGGACAAGTG GTCTTAACAG CAAGGAAAAC AAACACTTTA TGAAAACAGC 180
TATAAGCCTT CTGTCTTTTA TCTTTACTAT TTTCTCCGAG TCTGGCATGA AACAGATACA 240
CAGCAGCCTC CACAGGGGGT TAAGTARAGA ACCATCCAAG CATCACAGAG TGTCATCCAG 300
AATTCTGATG ACTTCCATTC GTTGACTCTG ATGCACAATA TGCCTGGCTT GGGATGCAGC 360
GACCATGATG CCCCTCCCAG AACAGACACT TGCAGAGTGT TCCAGGAACA GCAGCTCCCT 420
CCAGCCCCCA GCACAAGATG CACACATCTC AGAACAAGCC TCCATCCTTT TCCTAGAGAA 480
CTGAGCATAA ATAACTTGTT CTATATCTGG CTCCAAGTCC ATTTCTGTTC TGTCTTGGAG 540
TAGAGTCTTA GCTCCCAGTT TGTTTTAGGT CAACTTTCAG CACCTACTTC AGCTCACTTG 600
TTTGATTTAC TAAGCTCTTG CTTCTGTATA TTATCAAATG TAGGGATGTA GGGAGAATAA 660
AAGGATCTAG ATACTTGCTT TTAGGAGAGA TTAGAACAAA GCTGAAGGTG GAGGCATTAG 720
TTCCTAGGTC TTCAGATCTC AGAGCAAAGG ACCCACTCTG GAGCCTAAAT TCTATGAGAG 780
ACCACAGAGC AGCCTGAAAT CCAAAGGAGT TTTACACAGG AAAAAAAAAA TACTGTGAGG 840
ACTTACACTA AATAATAATG TTGTTTTGAA TGGGGTTGTG GGTAATTCCT ATATTCTTCT 900
TTATAACTTT TGTACTTTTC AAATTCCCTA ATGTGAACTC ACTACTTAGT AGGTCTGTAA 960
GCTTAAACAT TACTATGGCT TGGAATCTCA TTTCAAAAAA TCTTTAAAAT GGGGACAAGA 1020
GTAAAAATTT CTTAGCTTCT ATGGAAGAAT AAAATGAAAT TATAATGATA CAGTGCCTGG 1080
CATGTTGTGG TCGCTCAATA AACACTGCTT TCCTCCCCAT TGTCCTCCTC TTTATTCTGT 1140
TTCATT CAA GGTCAGCAGA TTGAATCAGG ACCAGCTGGG AGGGCTACTT CTATGAGAGA 1200
AGATCTGTCC ACAGTCATGG TTTTCAATGT TTAGTGCACC AGAATCACCT TGAGGGTTTG 1260
TTAAAACAGA CTGCTGAACA TAACACATCT ATGAGAATGG CCAAAATCCA GAACACCAAA 1320
TGCTGGTGAG GATGTGGAGC AATAAAAACT CTCATTTATT GCTGATGGCA ATGCAAAATG 1380
GTACAGCCAC TTTGGAAGAC AATTTGCCAA ATTTTTACAA AACTAAGTGT ACTCTTACCA 1440 TACAATCTAG CAATCATGCT CCCTGGTATT TACCTAAAGG AGTTAAAAAC TTATGTCTAG 1500
ACAGAAACCT GCATATGAAT GTTTATAGCA GTTTTTTTCA TAATTGCTAA ACTTTGGAAG 1560
TAACCAAGAT GCCCTTCAGC AGGTGAATGG ACAAATAAAC TGCAGTAGAT GCAGACAGTG 1620
GAATATCATT CTAGGCCATG AAGGCCGAAT TCGGCCTTCA TGGCCTAATT AAAGAAAGTC 1680
AGGATAAAAA TTTTAAAAAG CAGGCCACTG TCAGCAAAGC CTGGAGAAGT GGGGCCGGAG 1740
GYTCCGCCCC CATCATGTGC CTGCCACCCC TTCCCAGTCA TCCCTTTAYT CTTACAGTAG 1800
CAAATAAGAC CCCTGTCTAA TGGGGGGAGA CAAATGTGTA GACCCTTAGC CACCTTGGCC 1860
AGGGCTGACT CCTTAAATTT CTGGATGATG ATGATTGTTA TTTAATAGCC AGAGGCTCAT 1920
ATAATTGGCC TCTTTGGAAG AGGCCTCATG GCCTCCTTAC TCTCACCAAA GCAATTTTTC 1980
CCTCAGGGGG GCTCCCATCT TCTTACACAG AGAGGCAGCT GAGGCAGGAC AGTGGGGCTA 2040
ACTGTAGACC AGGCGAGGGC ACGGGCTGCT GGGGTGGCCC TGCTTCCCCA GTGTACATAT 2100
TGTATCTGTG TAACATTTTG TATATTCCAG GGGTAGGGCC GCCCCCTGTA TCATACCTAG 2160
CAGAGGTTGG AGCTGGCACA TGGGGAGGAG GTTCTAATAA TTATTTGGGG CTGGGAAACT 2220
TATTTATTGA TAGCATAGGA CAGAGGAAGG AGGCGGGGAT GGGGTCGTGG CGCCCTGGTG 2280
ATGCGACTCC TGTTTATTTT GCTTTTTATT TCGGAATAAA TGGATTTAGC CATAAAAAAA 2340
AAAAAAAAAA AAAAA 2355 ( 2 ) INFORMATION FOR SEQ ID NO : 2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 :
Met Lys Thr Ala lie Ser Leu Leu Ser Phe lie Phe Thr lie Phe Ser
1 5 10 15
Glu Ser Gly Met Lys Gin lie His Ser Ser Leu His Arg Gly Leu Ser 20 25 30
Xaa Glu Pro Ser Lys His His Arg Val Ser Ser Arg lie Leu Met Thr
35 40 45 Ser lie Arg 50
(2) INFORMATION FOR SEQ ID NO : 3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2496 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
GCGCCCTTTC GGTCAACATC GTAGTCCACC CCCTCCCCAT CCCCAGCCCC CGGGGATTCA 60
GGCTCGCCAG CGCCCAGCCA GGGAGCCGGC CGGGAAGCGC GATGGGGGCC CCAGCCGCCT 120
CGCTCCTGCT CCTGCTCCTG CTGTTCGCCT GCTGCTGGGC GCCCGGCGGG GCCAACCTCT 180
CCCAGGACGA CAGCCAGCCC TGGACATCTG ATGAAACAGT GGTGGCTGGT GGCACCGTGG 240
TGCTCAAGTG CCAAGTGAAA GATCACGAGG ACTCATCCCT GCAATGGTCT AACCCTGCTC 300
AGCAGACTCT CTACTTTGGG GAGAAGAGAG CCCTTCGAGA TAATCGAATT CAGCTGGTTA 360
CCTCTACGCC CCACGAGCTC AGCATCAGCA TCAGCAATGT GGCCCTGGCA GACGAGGGCG 420
AGTACACCTG CTCAATCTTC ACTATGCCTG TGCGAACTGC CAAGTCCCTC GTCACTGTGC 480
TAGGAATTCC ACAGAAGCCC ATCATCACTG GTTATAAATC TTCATTACGG GAAAAAGACA 540
CAGCCACCCT AAACTGTCAG TCTTCTGGGA GCAAGCCTGC AGCCCGGCTC ACCTGGAGAA 600
AGGGTGACCA AGAACTCCAC GGAGAACCAA CCCGCATACA GGAAGATCCC AATGGTAAAA 660
CCTTCACTGT CAGCAGCTCG GTGACATTCC AGGTTACCCG GGAGGATGAT GGGGCGAGCA 720
TCGTGTGCTC TGTGAACCAT GAATCTCTAA AGGGAGCTGA CAGATCCACC TCTCAACGCA 780
TTGAAGTTTT ATACACACCA ACTGCGATGA TTAGGCCAGA CCCTCCCCAT CCTCGTGAGG 840
GCCAGAAGCT GTTGCTACAC TGTGAGGGTC GCGGCAATCC AGTCCCCCAG CAGTACCTAT 900
GGGAGAAGGA GGGCAGTGTG CCACCCCTGA AGATGACCCA GGAGAGTGCC CTGATCTTCC 960
CTTTCCTCAA CAAGAGTGAC AGTGGCACCT ACGGCTGCAC AGCCACCAGC AACATGGGCA 1020
GCTACAAGGC CTACTACACC CTCAATGTTA ATGACCCCAG TCCGGTGCCC TCCTCCTCCA 1080
GCACCTACCA CGCCATCATC GGTGGGATCG TGGCTTTCAT TGTCTTCCTG CTGCTCATCA 1140 TGCTCATCTT CCTCGGCCAC TACTTGATCC GGCACAAAGG AACCTACCTG ACACATGAGG 1200
CAAAAGGCTC CGACGATGCT CCAGACGCGG ACACGGCCAT CATCAATGCA GAAGGCGGGC 1260
AGTCAGGAGG GGACGACAAG AAGGAATATT TCATCTAGAG GCGCCTGCCC ACTTCCTGCG 1320
CCCCCCAGGG GCCCTGTGGG GACTGCTGGG GCCGTCACCA ACCCGGACTT GTACAGAGCA 1380
ACCGCAGGGC CGCCCCTCCC GCTTGCTCCC CAGCCCACCC ACCCCCCTGT ACAGAATGTC 1440
TGCTTTGGGT GCGGTTTTGT ACTCGGTTTG GAATGGGGAG GGAGGAGGGC GGGGGGAGGG 1500
GAGGGTTGCC CTCAGCCCTT TCCGTGGCTT CTCTGCATTT GGGTTATTAT TATTTTTGTA 1560
ACAATCCCAA ATCAAATCTG TCTCCAGGCT GGAGAGGCAG GAGCCCTGGG GTGAGAAAAG 1620
CAAAAAACAA ACAAAAAACA AAACCCTGGA GTGTTAGGAG GAGAGTGAAG GTAGAGGGGT 1680
GAGGAAGGGT AAGGGGCAGG GCTGGTTTCA GCTGGGGGCT CTCACCAGCC CTCCTTTCAG 1740
CCTCTACAAC AGAGCAGCTT CCCAGACTTC TCCAGGAACC CAGAAACGGG ATGGTTGTCG 1800
GCAAAGGTTG GGAGTGGCTT TTCCTCTGGT AGCCACACAC CTGAGCACTA CGGACAGGGA 1860
GGCAGGTGCC ACCTTGACAC CTCTCTTCCA TAGCAATGGG AAAGTGATGA GTGCGGGAGT 1920
CCTGAGGAGA TGTGGCCTGC AGACAACATG CAGCCATGCA GGGACCCAGG ACTGTAACCT 1980
GGGGAGGACG CGGGTCCCTG CAAGGAAGAG TAGATTTGGA GAGGAAGGAT GGAGGTGGAC 2040
TCTCACCCCA TTCCCCCCGG AAATGAACAA AGCCGGGCCC TTTCCATAGG AACTGCCCTT 2100
GGAGATAGCA GAGTGTGGCT GCCCCTCCTT GCTCCAGCAG CAGTGGGAGA GGCACTGCTC 2160
TGGGGCCTGA ACTGCCTCTG CTTCCCCCCC TGAGGGGCCC CTCACTCTTA CCCAAGACTC 2220
TGGATTGTTG CACGGCAACC ACTCCTCCCA TGGCATTGCT CAGCAACTAC TTCTCCCTTC 2280
CCGGCCACCC TGTGCCCCCT TCCTGGTCCC AACGCCAGCC CTTCATCCTT CCTCCCTCAG 2340
CAGCCAGGCA GACATAACAA CAAAACTACT AAAAGGAGCT TCAAAAAAAA AAAAAAAAAA 2400
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2460
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAA 2496 (2) INFORMATION FOR SEQ ID NO : 4 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 398 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Met Gly Ala Pro Ala Ala Ser Leu Leu Leu Leu Leu Leu Leu Phe Ala 1 5 10 15
Cys Cys Trp Ala Pro Gly Gly Ala Asn Leu Ser Gin Asp Asp Ser Gin 20 25 30
Pro Trp Thr Ser Asp Glu Thr Val Val Ala Gly Gly Thr Val Val Leu 35 40 45
Lys Cys Gin Val Lys Asp His Glu Asp Ser Ser Leu Gin Trp Ser Asn 50 55 60
Pro Ala Gin Gin Thr Leu Tyr Phe Gly Glu Lys Arg Ala Leu Arg Asp 65 70 75 80
Asn Arg lie Gin Leu Val Thr Ser Thr Pro His Glu Leu Ser lie Ser 85 90 95 lie Ser Asn Val Ala Leu Ala Asp Glu Gly Glu Tyr Thr Cys Ser lie 100 105 110
Phe Thr Met Pro Val Arg Thr Ala Lys Ser Leu Val Thr Val Leu Gly 115 120 125 lie Pro Gin Lys Pro lie lie Thr Gly Tyr Lys Ser Ser Leu Arg Glu 130 135 140
Lys Asp Thr Ala Thr Leu Asn Cys Gin Ser Ser Gly Ser Lys Pro Ala 145 150 155 160
Ala Arg Leu Thr Trp Arg Lys Gly Asp Gin Glu Leu His Gly Glu Pro 165 170 175
Thr Arg lie Gin Glu Asp Pro Asn Gly Lys Thr Phe Thr Val Ser Ser 180 185 190
Ser Val Thr Phe Gin Val Thr Arg Glu Asp Asp Gly Ala Ser lie Val 195 200 205
Cys -Ser Val Asn His Glu Ser Leu Lys Gly Ala Asp Arg Ser Thr Ser 210 215 220
Gin Arg lie Glu Val Leu Tyr Thr Pro Thr Ala Met lie Arg Pro Asp 225 230 235 240
Pro Pro His Pro Arg Glu Gly Gin Lys Leu Leu Leu His Cys Glu Gly 245 250 255
Arg Gly Asn Pro Val Pro Gin Gin Tyr Leu Trp Glu Lys Glu Gly Ser 260 265 270 Val Pro Pro Leu Lys Met Thr Gin Glu Ser Ala Leu lie Phe Pro Phe 275 280 285
Leu Asn Lys Ser Asp Ser Gly Thr Tyr Gly Cys Thr Ala Thr Ser Asn 290 295 300
Met Gly Ser Tyr Lys Ala Tyr Tyr Thr Leu Asn Val Asn Asp Pro Ser 305 310 315 320
Pro Val Pro Ser Ser Ser Ser Thr Tyr His Ala lie lie Gly Gly lie 325 330 335
Val Ala Phe lie Val Phe Leu Leu Leu lie Met Leu lie Phe Leu Gly 340 345 350
His Tyr Leu lie Arg His Lys Gly Thr Tyr Leu Thr His Glu Ala Lys 355 360 365
Gly Ser Asp Asp Ala Pro Asp Ala Asp Thr Ala lie lie Asn Ala Glu ' 370 375 380
Gly Gly Gin Ser Gly Gly Asp Asp Lys Lys Glu Tyr Phe lie 385 390 395
(2) INFORMATION FOR SEQ ID NO : 5 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2764 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 :
GGGCCAAAGA GGCCTACCAG CTGCTGTTGA CCGCTGGACT CACAAACCTT TCTTTCTACT 60
CTTGTTTTTC ATTCACTTTG GGTCATTTTT CAGTGTTGAT GGGGACGTAA TAAAGCACGG 120
TAAGAAAATC CGTGAATTCC GTCAGAGCAG TCGTCCAGAG GGAAGGCGCG CCCGGCGTAG 180
GGAGGTCAGA GCTCATGTTA GCTATGAACA CAGGTCACAG GGGCGTACGG CGATGGGAAA 240
CACTGAGATG CTCAATATAT TGATTATTTA ATAGTGTTTA GCAAAATGGT CTTTTTTTAT 300
TCCTTAAATC AACTGAAACT CACTTCACGT CTCTTTCCTT GTAGAGCATC ATGCTTATTT 360
CTGGCTCACT CACATCTTTG TCTCGGGAGT TCTCTGCCGA GCCATTGCCC CCTACAGCAG 420
AGAGCACAGC TGGCTGCACT AGTGCTGAAG GAGCCAGCCC CAGAGCAGGG CATTTCCAGG 480 GGCTCTTGTC CCAGAGCGGC AGGCGTTGTG TGCAGAGAAC GCCCCTCCCA CGCAGCACAG 540
AGAACGCGGG GTGGGTGTGT GGCTCCGGGC CTGTGGGGCT TAGGCTGCCT GAACCACCGC 600
CGACTGGCAC CATGACTCGG CATTCCTGGA AGTGCCTTAC CAAGTTGTTG TTGTTGTTTT 660
GTTGTTTTTT AAGAGACGGG CTTGCTCTAT CATCCAGGCT CGAGTGCAAT GGCACAGTCA 720
CAGCTCACTG CAGCCTTGAA CTCGTGGGCT CAAGCCATCC TCCTGTGTCA GCCTCCCCAG 780
TACCTGGGAC TGTGGGCATG AGCACTGCGC CTGGCAGCTG TATCAGTGTT GACTCCACAT 840
TTTAATAGTT GCTTCTTGAA ATTAAAATGC TTTGATTCAG CCTTCAAGCC ATCAGGAAAG 900
TTTGCCCCTC TGAGTCACAC CTGGTGGTCT CCAGGGTTCC TGCCCCTCCC TCCTGAGCCA 960
GCTCCTCAGA GCGGATAGAG GCAGGACCCC CACCCAGGTC TTGAGACCCC CCTGCCCCGC 1020
ACTCCCCCGG AGACGGGCTA CCCCTGCAGA TGCAGATAGT CAAAGCTCAG GTTTCTTCCA 1080
AAGCTTTTAA AAAGATATTG TACCTTGAGC ACTTTAAAAA TGTCTTAAAA TTGCCATACA 1140
GGCTCTTAAA AGCTTATACG TTTAAACTGT TGATAGATGG GCCTTTACTA AAATGCATTC 1200
ATTTATTTTC CTAATCCCTT GGTTGTTAAA TAATTCTGGG GAAGGGCCCC GAGCACGACA 1260
GCCGCAGTCT CCACCCAGAA CCAGAGAGTC CCCCCCAACC CGGGATGTAC CCTCTGGCCA 1320
CACCAGGGAC CCTGCCAGAG GCCGCAGACT GGCAGCAGCA GCCTCCCCAC ACAGTGGGGG 1380
AAGGTCAGTG TGATGCCTTC AGGCCCCGTC TCCTGCCAGG GCTCTCCCTC CAGCCTACAT 1440
AGGGCCTCAG AGAAATGCAT TTTTAGTTCT GGCTTTGGCC CAGCCCAGGG CAAGGCAGGA 1500
AACTCTCCAG CGTGAGTCCG TGAGGGCCAA GAAGTCCCGC CCTGTTCTGG GGGAGGACCT 1560
GGCTTTTCTG GTGTCTCTGG TGCCCGAGAG CCCGGTGCTG CCATCTTTAG TGAAAGAGTA 1620
AATGGTGGCC GAGGGCTCCT TTTGTGAGGG ATGTGCCTTG GTGAAGAAGG CATGTTCCCT 1680
GCCGTGAAGA TACTTGGAAG CTCTGGGTGG AGAGGGAAAA GGGATACCCC TGGTGCTCCC 1740
TGGGCCTGGC GGAAGGCTAG GAGGAAGGAC AGCTGAGGTG AGGACTGAGT GGGGCAGGTA 1800
TCACCCTGAC AAACAGTTTG GGAAGATCAG GAAAGGCAGG TGAGACCTGG TGCAGAATCC 1860
AGGTTGGGTA ATAGATACAT CGTCGAAGAT GTAGCAAGCA AAGTAATATA CTCAACTCTG 1920
GAACATTGCA CAGAAGCTTT TAAAGCACTC TGTGACACTT TTTGTAATGA GGGATCTGAA 1980
GGAAACGGCC CCAGAGTCAC CCATCCCCAC GGGTCTGGTT GGCGGGGCTG GTGCCTTTCT 2040
TCTGCACTCA GTCACCATGG CTCCGTCTGT CAAACTCAAC TCTTTTTTTT TTTTTTTTTC 2100
TTCTCTTGGT GTGGTAATTT GTTTGAAGAG CCACTCCATC CCCAAATTCA AGATTAGAAA 2160 GATCCCTGAC TGCTTCTCAA GATCCAGAAC ATTCCTTGAC AGAGTATATT CACCATTTAG 2220
AAGTGATCCA GCAAAGATTG GGAGGGGTAC TACCAGATTC TACTTCAAAG AAATCCTGCC 2280
ACCCGATGAT TAAACAGTGA ATAAAATGTC ATGGCTCTTT CCTGCGACAA TTCTATTTGA 2340
GGAAAAGATT TGTTTTTCCC TTTTCCCAAG GAAGCTCGTG GGACAGCATG GGCACTACTC 2400
TTCATGTGCG GTGACACCAG CCCCCAGATG CCTTGAATTA AGTGTCCTCA CCTTTATGCA 2460
TGACTGCAAA GCCAGCTGGA GCATTTTCTA TGGAGCCTCC GTATGTTTTA GGCCCATGAC 2520
CTTCGTGAGG TGATGGGCAC TCACTCCCAT GAGCCCTGGC TGTGTGCTGT TGTGTGCCTA 2580
TCGGCAGATC CATCCTTCCT GCCTCCAAGG AGGATACACA GAGAATGGCT TCCTGTTGTT 2640
TTGTTTATTT TCTTAACGTG TACAGATGGA AACTTCATTT AAAAATAAAA ACAAAACAAY 2700
TCNAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2760
AAAA 2764 (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 164 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 :
Met Leu lie Ser Gly Ser Leu Thr Ser Leu Ser Arg Glu Phe Ser Ala 1 5 10 15
Glu Pro Leu Pro Pro Thr Ala Glu Ser Thr Ala Gly Cys Thr Ser Ala
20 25 30
Glu Gly Ala Ser Pro Arg Ala Gly His Phe Gin Gly Leu Leu Ser Gin 35 40 45
Ser Gly Arg Arg Cys Val Gin Arg Thr Pro Leu Pro Arg Ser Thr Glu 50 55 60
Asn Ala Gly Trp Val Cys Gly Ser Gly Pro Val Gly Leu Arg Leu Pro 65 70 75 80
Glu Pro Pro Pro Thr Gly Thr Met Thr Arg His Ser Trp Lys Cys Leu 85 90 95 Thr Lys Leu Leu Leu Leu Phe Cys Cys Phe Leu Arg Asp Gly Leu Ala 100 105 110
Leu Ser Ser Arg Leu Glu Cys Asn Gly Thr Val Thr Ala His Cys Ser 115 120 125
Leu Glu Leu Val Gly Ser Ser His Pro Pro Val Ser Ala Ser Pro Val 130 135 140
Pro Gly Thr Val Gly Met Ser Thr Ala Pro Gly Ser Cys lie Ser Val 145 150 155 160
Asp Ser Thr Phe
(2) INFORMATION FOR SEQ ID NO : 7 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3367 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
CAGAAGGGAG GTAGTCGCCC TCCGTCGTGG CCTGGCGTGG ATTCCGAGCG TTGGTGTCTG 60
GCGGTTTCCG ACCGTTGGTG TCTGGCACGC GCCACCCCGA TGTACCAGGT AAAGCCCTAT 120
CACGGGGTCG GCGCCCCTCT CCGTGTGGAG CCCACCTGCA TGTACTGGCT CCCCAACATG 180
CACGGCAGGA GCGGCGGCCC AGCACTCGGC ACTGGCCACT TGCAGACAAG AAGACAAGAA 240
AATGATTTGA GGACAGCTTC AATCGCGGTG TGAAGAAGAA AGCAACAAAA CGACCACTGA 300
AAACAATGCC GGTGGCAAAA CATCCAAAGA AAGGGTCCCA AGCGGTACAT CGTCATAGCT 360
GGAAACAGTC AGAGCCACCA GCCAATGATC TTTTCAATGC TGCGAAAGCT GCCAAAAGTG 420
ACATGCAGTG TGGCCATGAG GTCTGCCGGA AGTGACTTGT TGGTGTTATC TCCTGAGTTA 480
AAATGTGAAG GGATTTTTTT TTTTCAGATT ACTGAGAGTC TTCTGTTACT AGTTTGTCTT 540
TCCTAGATCC AGACACGGGG ACTGCAGAGA AAGGCTGTGT GCATCCGCTG TCTACTCCAC 600
TGTCTCCTCT GCAGAGGCGG ATTTCCCTGA CTGAAGACCA TGTTGCAGGC CCACAGCTGC 660
CTACAGAACC GTCCCAAAAT ATGGCAAAGA AACCTATTCT GAGGGTCTCA CCATGTTGCC 720
CAGGCTGGTC TTGAACTCCT GGACTCATCC TAAAGTGCTG GCCTCTCATT CCCTGTCTGT 780 GCACACCTCA CGGCAAGGGC CAGCCTGTTT CCTCCCGGTC ACCTCCAAAT CTTGCTGCTT 840
TTAATTCAAC TCAGAGGCCT AGCCAGGGTT GAGTTCTCAC CCACCTGTGC CGCCCTGCCT 900
TGTTACCTGG AAGCACAGCC TTGGGGACTG AGCAGGCCCT CACTGTCACT TTAAGAAGGG 960
AATCAGCCAC TTTGTGCTCA CCACCTCTGG GGAAGGTGTG AGAGGAGAGA AGGAAGTGGC 1020
TGTTTGGCTG CTGACAACAT GAAGACTTCC TGCGATGAGA ACAGAGGCAC AGGTGCCGGC 1080
CCTGCAGCCC CCAGAACCCG GACTGGAGGG GGCCATGGGG CGCCGGACCC TGGCCCTGCC 1140
CTGGGTGCTG CTGACCCTGC GTGTCACTGC AGGGACCCCG GAGGTGTGAG TACAAGTTCG 1200
GATGGAGGCC ACCGAGCTCT CGTCCTTCAC CATCCGTTGT GGGTTCCTGG AGTCTGGCTC 1260
CATCTCCCTG GTGACTGTGA GCTGGGGGGG CCCCGATGGT GCTGGGGGGA CCACGCTGGC 1320
TGTGTTGCAC CCGGAACTTG GCATCCAGCA ATGGGCCCCT GCTCGCCAGG CCCGCTGGGA 1380
AACCCAGAGC AGCGTCTCTC TTGCCCTGGA AGTCTCTGGG GCCAGCAGCC CCTGCACCAA 1440
CACCACCTTC TGCTGCAAGT TTGCGTCCTT CCCTGAGGGC TCCTGGGAGG CCTCTGGGAG 1500
CCTCCCGCCC AGCTCAGACC CAGGGCTCTC TGTCCCGCCG ACTCCTGCCC CCATTCTGCG 1560
GGCAGACCTG GCCGGGATCT TGGGGGTCTC AGGAGTCCTT CTCTTTGACT GTGGCTACCT 1620
CCTTCATCTG CTGTGCCGAC AGAAGCACCG CCCTGCCCCT AGGCTCCAGC CATCCCACAC 1680
CAGCTCCTAG GCACTGAGAG CACGAGCATG GGCACCCAGC CAGGCCTCCC AGGCTGCTCT 1740
CCACGTCCCT TATGCCACTA TCAACACCAG CTGCTGCCCA GCTACTTTGG ACACAGCTCA 1800
CCCCCGACAG GGGGCCGTCC TGTCGTTTCC TGCTGTGACT AAGTCAGCAA CACAGTTCCT 1860
CTGACATGGG CCTTGGCTGT GCTTCTTTGG GGGTGAAGAG ATTGGGGAGG AAGTCTCCAC 1920
CCCTGGGAGG CAGAAGCCAG GCATAGCGCG CTGGCTAGGA CTCCAGTACC GTGAAGGGAG 1980
GCAGTGAGAG CAGACATCTG TGTCTCATTC CTGATCTCAA GGGGAAAGCA AGAACAAGGG 2040
AGGCTTCCTC AGGATCTCAA ACCTGCGGAA GGAGGACCAG TCTGTGTACT TCTGCCAAGT 2100
CCAGCTGGAC ATACAGATCA GCCCTCAGGC AGCCCCTCCA CAGGACCCCT CTCCTGCCTG 2160
GACAGCTCTG CTGGTCTCCC CGTCCCCTGG AGAAGAACAA GGCCATGGGT CGGCCCCTGC 2220
TGCTGCCCCT GCTGCTCCTG CTGCAGCCGC CAGCATTTCT GCAGCCTGGT GGCTCCACAG 2280
GATCTGGTCC AAGCTACCTT TATGGGGTCA CTCAACCAAA ACACCTCTCA GCCTCCATGG 2340
GTGGCTCTGT GGAAATCCCC TTCTCCTTCT ATTACCCCTG GGAGTTAGCC ACAGCTCCCG 2400
ACGTGAGAAT ATCCTGGAGA CGGGGCCACT TCCACGGGCA GTCCTTCTAC AGCACAAGGC 2460 CGCCTTCCAT TCACAAGGAT TATGTGAACC GGCTCTTTCT GAACTGGACA GAGGGTCAGG 2520
AGAGCGGCTT CCTCAGGATC TCAAACCTGC GGAAGGAGGA CCAGTCTGTG TATTTCTGCC 2580
GAGTCGAGCT GGACACCCGG AGATCAGGGA GGCAGCAGTT GCAGTCCATC AAGGGGACCA 2640
AACTCACCAT CACCCAGGCT GTCACAACCA CCACCACCTG GACGCCCAGC AGCACAACCA 2700
CCATAGCCGG CCTCAGGGTC ACAGAAAGCA AAGGGCACTC AGAATCATGG CACCTAAGTC 2760
TGGACACTGC CATCAGGGTT GCATTGGCTG TCGCTGTGCT CAAAACTGTC ATTTTGGGAC 2820
TGCTGTGCCT CCTCCTGTGG TGGAGGAGAA GGAAAGGTAG CAGGGCGCCA AGCAGTGACT 2880
TCTGACCAAC AGAGTGTGGG GAGAAGGGAT GTGTATTAGC CCCGGAGGAC GTGATGTGAG 2940
ACCCGCTTGT GAGTCCTCCA CACTCGTTCC CCATTGGCAA GATACATGGA GAGCACCCTG 3000
AGGACCTTTA AAAGGCAAAG CCGCAAGGCA GAAGGAGGCT GGGTCCCTGA ATCACCGACT 3060
GGAGGAGAGT TACCTACAAG AGCCTTCATC CAGGAGCATC CACACTGCAA TGATATAGGA 3120
WTGAGGTCTG AACTCCACTG AATTAAACCA CTGGCATTTG GGGGCTGTTC ATTATAGCAG 3180
TGCAAAGAGT TCCTTTATCC TCCCCAAGGA TGGAAAATAC AATTTATTTT GCTTACCATA 3240
CACCCCTTTT CTCTTCGTCC ACATTTTCCA ATCTGTATGG TGGCTGTCTT CTATGGCAGA 3300
AGGTTTTGGG GAATAAATAG CGTGAAATGC TAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3360
AAAAAAA 3367 (2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 226 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS :
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8 :
Met Gly Arg Pro Leu Leu Leu Pro Leu Leu Leu Leu Leu Gin Pro Pro 1 5 10 15
Ala Phe Leu Gin Pro Gly Gly Ser Thr Gly Ser Gly Pro Ser Tyr Leu 20 25 30
Tyr Gly Val Thr Gin Pro Lys His Leu Ser Ala Ser Met Gly Gly Ser 35 40 45 Val Glu lie Pro Phe Ser Phe Tyr Tyr Pro Trp Glu Leu Ala Thr Ala 50 55 60
Pro Asp Val Arg lie Ser Trp Arg Arg Gly His Phe His Gly Gin Ser 65 70 75 80
Phe Tyr Ser Thr Arg Pro Pro Ser lie His Lys Asp Tyr Val Asn Arg 85 90 95
Leu Phe Leu Asn Trp Thr Glu Gly Gin Glu Ser Gly Phe Leu Arg lie 100 105 110
Ser Asn Leu Arg Lys Glu Asp Gin Ser Val Tyr Phe Cys Arg Val Glu 115 120 125
Leu Asp Thr Arg Arg Ser Gly Arg Gin Gin Leu Gin Ser lie Lys Gly 130 135 140
Thr Lys Leu Thr lie Thr Gin Ala Val Thr Thr Thr Thr Thr Trp Thr 145 150 155 160
Pro Ser Ser Thr Thr Thr lie Ala Gly Leu Arg Val Thr Glu Ser Lys 165 170 175
Gly His Ser Glu Ser Trp His Leu Ser Leu Asp Thr Ala lie Arg Val 180 185 190
Ala Leu Ala Val Ala Val Leu Lys Thr Val lie Leu Gly Leu Leu Cys 195 200 205
Leu Leu Leu Trp Trp Arg Arg Arg Lys Gly Ser Arg Ala Pro Ser Ser 210 215 220
Asp Phe 225
(2) INFORMATION FOR SEQ ID NO : 9 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3899 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 : GGGAAGAGAT GGTGACTGAG GCAGAAGCTA ATAGGGAAGA TGATAGGAAA GAAATTTTAC 60 CCAAGGGAAT TAGATTTAGC AAGAGAGCGA AGGAAAGCTG AGAGGCCAAA AACATCTCTG 120 AGGAAAACTG ACTCTGAGAG AGAAGAGGTG ACAAGGGCAA ATGCACTCAA GGATGAAGAT 180
GCTTTTAAAG AAGAGCAAAA ACTTAAAGCG GAAGAAGGGG AAACAGAGAC AGAAGTWAGA 240
GCTGAGGAAG AGACAAAAGC TCCCCCAAAT GAAATGGGAT CTGATGCTGA RAACGAASCA 300
CCTGTGGAGG CTTCTGAGTT GTCTGACAAT CCAGGGCTTC TAGGAGAARA TTCACTAAAA 360
GAGACAGTGG TTCCCATATT TGAAGCAACG CCTGGATTTG AAAAGTCGCT GGAAAACATA 420
ACAGCTCTGA GGAAAGAAGG AGGAGGGGAA AGACTGAGTG AAGCCAGAGA CACAGAGCAC 480
AAAGACAGAG AAGAGCTGTC CAGCAGGGAG AATAGGGCCC TGAAGGAAGG GCACCGCCAA 540
GATGGAGAGG GGGCCTTAGC AGCTCCTGAA GCTGAGCCAG CAGGAAAGGT GCAGGCCCCT 600
GAGGGGCTGA TCCCAGCCAC AGGCCAGGCA GAGGAGCTAG CAGCCAAAGA TCACGACTCC 660
TGCGCAGGAC TGGAGGGGAG AGCTGAAGGG CAAGGAGGAG TGGATGTCGT GCTAAGGACC 720
CAGGAAGCTG TTGCTGAGGA AGATCCCATA WTGGCAGAAA AGTTCAGGGA GGAAGCGGTG 780
GATGAGGACC CAGAGGAGGA AGAGGACAAA GAGTGCAYTC TGGAGACAGA AGCGATGCAG 840
GACAGGAACT CGGAAGGGGA CGGGGACATG GAAGGAGAAG GAAACACACA AAAGAATGAG 900
GGCATGGGAG GAGGAAGGGT TGTGGCTGTG GAAGTTCTAC ACGGAGGTGG TGAAACGGCA 960
GAAACAGCCG CAGAGGAGAG GGAGGTGTTG GCAGGTTCGG AGACAGCCGA GGAGAAAACA 1020
ATAGCAAATA AAGCCTCCTC CTTTTCAGAT GTTGCTGAGG AAGAAACCTG GCACCAACAG 1080
GATGAGTTAG TAGGAAAAAC AGCAGCTGCA GGGAAGGTGG TGGTAGAGGA ATTAGCACGG 1140
AGTGGGGAGG AAGTGCCAGC AGCAGAGGAG ATGACAGTGA CATATACAAC AGAGGCTGGG 1200
GTGGGCACTC CAGGAGCCCT GGAGCGGAAG ACCTCAGGGC TAGGACAGGA GCAAGAGGAA 1260
GGGTCAGAGG GCCAGGAGGC AGCCACTGGG AGTGGCGATG GGAGGCAGGA GACAGGAGCA 1320
GCTGAAAAAT TCCGATTAGG ATTATCACGG GAGGGAGAGA GGGAATTGAG TCCGGAGAGT 1380
CTACAGGCGA TGGCAACACT TCCAGTGAAG CCTGATTTCA CTGAAACCCG AGAGAAGCAA 1440
CAGCATATGG TGCAAGGAGA AAGCGAGACT GCAGATGTTT CCCCCAACAA CATGCAGGTC 1500
TAGGAGACTT GCTGGCAGAC GGATAATTTA AAGATGTCTT CTGAAGATGT AAAGAGTGGA 1560
GAAAGATTCA CGCAAGCATC TCACCAGGAT TCTTGATTTT CTCTCTCTCC TCTTTAGTTG 1620
CTGGTTGCGC TTGTCTGAGA TGATTCCCAA TCTGTCAGCC CTGGTCAGTA GCTCAGTAAG 1680
CACCTTGAGA ATAGCTCAAG TAGATCTGTA GGACCCTTCT TAGAAGCAGT GGTTCCTCAT 1740
GGAGAAACTT GTGAGGCTGT TACACATTCT ACACACCTAA CATTATTTTC AAACAAAAAT 1800 GATAATTTTC AGATGCTTGA CTTTTACCAA AGATCACTGG AAGGCCCAGT CCTAATGTTA 1860
GGGGTTTGTT TAAAGTCCTT TTTATTTTAC AATACAGAGC CCCAGTCAAT TCCACAATCT 1920
CAATTTCATA CATGGGAATT TTATTTAAAA ATCTGTGGTT TGGGGCTTTA ATGAATTGGC 1980
CTGTGAAAAT GAGCTCTAAA TTTCCTCCCA CGTACACTCA AAACTCAAGA TTGCTCCAAA 2040
TCTCTAAGTT CTTCCAGCAA AAGATTTCTT GGCATGTATA TTCACTTATA CTTAGAAATA 2100
TTCATTCTTT TAATTTATGC CAGAATAACA AAGTGGAAAT CTTATTTCAA AATGCTCTTT 2160
GTTTTTTTGT GTGTGTTTCT GTAGTTCTGC TTTCTGGGGT AGACTAGTAA AATGGTAGCT 2220
TCCAGCATTT TGTCCCTGGG GCCTTCTTTA TAGGGCCACT CAAATTTAAA TAAAAGTAGT 2280
AAATAATTTA GCTAAGTGGA ATAAGTATAA TAATTATAGT GGTAAGC TA GCACATCAGC 2340
ATTATGCCAA CATTCTAGAC TCTTTAGTTG ATGTCATTAA ATGGAAAAGA AACTTGGATT 2400
AAATGAGTGT GCTGCTCACC TTCCCAAGTT CTGTTATTTC AAACCTGTGA ACTAACCTTG 2460
CAGTTCATTA TAAATCAACA GTAACAACTG CATTCTAAAT TACTCCCTGA TATTATTTTC 2520
TAGTTGTGTA TCAGCCTGTC TCCTAGGGGT TTTCATTTCC CTGAAGACAT ACAAGTGCCC 2580
CAGAGCGCAT GTATATGTCT ACCATTTCTC TATATGAGAA GGTAAAAAAA ATTTCCTTAA 2640
GCAGTGATTT TCCAGCCAGA ATATACATTA GATTTTCATG GGACGCTTTT ATAAATGACT 2700
CAACCCTTTT CCCCACCCCA GAGATTCAGA CTTAATTCGT TTTAGATGGA TCTACACATC 2760
AGTATATATA TATTTTTAAC TTTTCACTTG ATTCTTCTCT GTAGCCAAGG TTGAGAACCG 2820
CTGTTCTAAA TCATCATATA ATCCATGCTG GCCACATTAC ACTCAAGGTC CCTAGGGACC 2880
AGGCATATTA TCATAGTAGG TATCTTCCAT TTTAATGTGT AATGGAGCCA TTCAATGATC 2940
AAAAATACAC TGGACCAGAT AGTAGACTGG TCCCTTGATC AGAAGCATCA GCACATCAGC 3000
ATCACCTGGA AATTGTTCCC AGCCTTTGTC TCCTACCTAC TAAATTAGAA ACTCTTGGTG 3060
GGTTCCAGTA ATCCATAGCT TAACAAGCCC TGCAGTTAAT ACTGATGTAC ACTGATGTCC 3120
AAAAACTGCT GTCATGGACT ATTGATTGTA TTGAGGATTA GTCTCAGTTG GAAAGCCAAC 3180
TACAGAGGCA TTTTGAACTT TCTTTCTTTG CCTCTCTATG TCTCTCTGTC TTTTCCTGTC 3240
TTCTGATTTA TCTGTCTTTC TTTCTCTAGT AAATGGCACT CAATATAAAA GTGGTGGAGT 3300
CAATCTTAAA CTTATTTTTA TTATGATTGT ATTGATACAT GCACGAAGTC CCTCTGCCCT 3360
ACTCCCTATT CAAGGATATT ACTCACTGCA CATCATAAAT CTCCATCATC TGTCTTAAAG 3420
TTTTATGAGT AGATTTCATC TACATTATAT TCAAGTTCAT TTATTACTGA GCTGTATTAC 3480 TGTGGAGCTC TAACAGTATT TGTTTCCTGA TTTCAAACTC AATGCTACAG AGCACTTTGA 3540
ATACATCACA CCTTATAGGA AAGATAGTAA ATGTATTAAT CCCATTGAAA AATTAGTTTT 3600
GTACAATGTG CTAAATAGTA TTGCATTGGA TTACTTTTAT ATTTAACACA CTCCATCAAA 3660
ACATCCCATA ACATAATTTT ACAATCTGCA TGTGAATTTA ACTGTGAAAT TCAGTATTGT 3720
GATATTTTGA ATAAGTGAAT TCTTTCTCTG CAAATACTAT GTTGATAAAA TTACTTGTAT 3780
GTTCCCCTGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3840
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAGA 3899 (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 487 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Met lie Gly Lys Lys Phe Tyr Pro Arg Glu Leu Asp Leu Ala Arg Glu 1 5 10 15
Arg Arg Lys Ala Glu Arg Pro Lys Thr Ser Leu Arg Lys Thr Asp Ser 20 25 30
Glu Arg Glu Glu Val Thr Arg Ala Asn Ala Leu Lys Asp Glu Asp Ala 35 40 45
Phe Lys Glu Glu Gin Lys Leu Lys Ala Glu Glu Gly Glu Thr Glu Thr 50 55 60
Glu Val Arg Ala Glu Glu Glu Thr Lys Ala Pro Pro Asn Glu Met Gly 65 70 75 80
Ser Asp Ala Glu Asn Glu Xaa Pro Val Glu Ala Ser Glu Leu Ser Asp 85 90 95
Asn Pro Gly Leu Leu Gly Glu Xaa Ser Leu Lys Glu Thr Val Val Pro 100 105 110 lie Phe Glu Ala Thr Pro Gly Phe Glu Lys Ser Leu Glu Asn lie Thr 115 120 125
Ala Leu Arg Lys Glu Gly Gly Gly Glu Arg Leu Ser Glu Ala Arg Asp 130 135 140 Thr Glu His Lys Asp Arg Glu Glu Leu Ser Ser Arg Glu Asn Arg Ala 145 150 155 160
Leu Lys Glu Gly His Arg Gin Asp Gly Glu Gly Ala Leu Ala Ala Pro 165 170 175
Glu Ala Glu Pro Ala Gly Lys Val Gin Ala Pro Glu Gly Leu lie Pro 180 185 190
Ala Thr Gly Gin Ala Glu Glu Leu Ala Ala Lys Asp His Asp Ser Cys 195 200 205
Ala Gly Leu Glu Gly Arg Ala Glu Gly Gin Gly Gly Val Asp Val Val 210 215 220
Leu Arg Thr Gin Glu Ala Val Ala Glu Glu Asp Pro lie Xaa Ala Glu 225 230 235 240
Lys Phe Arg Glu Glu Ala Val Asp Glu Asp Pro Glu Glu Glu Glu Asp 245 250 255
Lys Glu Cys Xaa Leu Glu Thr Glu Ala Met Gin Asp Arg Asn Ser Glu 260 265 270
Gly Asp Gly Asp Met Glu Gly Glu Gly Asn Thr Gin Lys Asn Glu Gly 275 280 285
Met Gly Gly Gly Arg Val Val Ala Val Glu Val Leu His Gly Gly Gly 290 295 300
Glu Thr Ala Glu Thr Ala Ala Glu Glu Arg Glu Val Leu Ala Gly Ser 305 310 315 320
Glu Thr Ala Glu Glu Lys Thr lie Ala Asn Lys Ala Ser Ser Phe Ser 325 330 335
Asp Val Ala Glu Glu Glu Thr Trp His Gin Gin Asp Glu Leu Val Gly 340 345 350
Lys Thr Ala Ala Ala Gly Lys Val Val Val Glu Glu Leu Ala Arg Ser 355 360 365
Gly Glu Glu Val Pro Ala Ala Glu Glu Met Thr Val Thr Tyr Thr Thr 370 375 380
Glu Ala Gly Val Gly Thr Pro Gly Ala Leu Glu Arg Lys Thr Ser Gly 385 390 395 400
Leu Gly Gin Glu Gin Glu Glu Gly Ser Glu Gly Gin Glu Ala Ala Thr 405 410 415
Gly Ser Gly Asp Gly Arg Gin Glu Thr Gly Ala Ala Glu Lys Phe Arg 420 425 430
Leu Gly Leu Ser Arg Glu Gly Glu Arg Glu Leu Ser Pro Glu Ser Leu 435 440 445
Gin Ala Met Ala Thr Leu Pro Val Lys Pro Asp Phe Thr Glu Thr Arg 450 455 460
Glu Lys Gin Gin His Met Val Gin Gly Glu Ser Glu Thr Ala Asp Val 465 470 475 480
Ser Pro Asn Asn Met Gin Val 485
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 483 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
CATTGCTAGA CAGACTCTCT TGCTTGGATG GTACTCCACC ACTTTCTTGG CACATGAGAT 60
GCAAGATTGC TCAGGGTGCA GCTAATGGCA TCAATTTTCT ACATGAAAAT CATCATATTC 120
ATAGAGATAT TAAAAGTGCA AATATCTTAC TGGATGAAGC TTTTACTGCT AAAATATCTG 180
ACTTTGGCCT TGCACGGGCT TCTGAGAAGT TTTGCCCAGA CAGTCATGAC TAGCAGAATT 240
GTGGGAACAA CAGCTTATAT GGCACCAGAA GCTTTGCGTG GAGAAATAAC ACCCAAATCT 300
GATATTTACA GCTTTGGTGT GGTTTTACTA GAAATAATAA CTGGACTTCC AGCTGTGGAT 360
GAACACCGTG AACCTCAGTT ATTGCTAGAT ATTAAAGAAG AAATTGAAGA TGAAGAAAAG 420
ACATTGAAGA TTATATTGAT AAAAAGATGA ATGATGCTGA TTCCACTTCA GTTGAAGCTA 480
TGT 483 (2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 121 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
Met Ala Ser lie Phe Tyr Met Lys lie lie lie Phe lie Glu lie Leu 1 5 10 15
Lys Val Gin lie Ser Tyr Trp Met Lys Leu Leu Leu Leu Lys Tyr Leu 20 25 30
Thr Leu Ala Leu His Gly Leu Leu Arg Ser Phe Ala Gin Thr Val Met 35 40 45
Thr Ser Arg lie Val Gly Thr Thr Ala Tyr Met Ala Pro Glu Ala Leu 50 55 60
Arg Gly Glu lie Thr Pro Lys Ser Asp lie Tyr Ser Phe Gly Val Val 65 70 75 80
Leu Leu Glu lie lie Thr Gly Leu Pro Ala Val Asp Glu His Arg Glu 85 90 95
Pro Gin Leu Leu Leu Asp lie Lys Glu Glu lie Glu Asp Glu Glu Lys 100 105 110
Thr Leu Lys lie lie Leu lie Lys Arg 115 120
(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 493 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
AATCTGAGTC AGCTTAGAAG ATANTCCAAG CTTCAGATGA TAACCACAGC CTGGGCTGAC 60
ACCTGGATTT CAGCTTTGCA TGATCCTCAG TATGAGAATC TATCTGTTCT GTGCTGGACT 120
TCTAATATAT AGAACTGTGA GATAATGGGT CACATTGGCT GGATGTGGTG GCTCATACCT 180
GTAAATCCCA GCACTTTGGG AGGCCGAGGC AGGCAGATCA CCTGAGGTCA GGAGTTCAAG 240
ACCGGCCTGG CCAGCATGGT GAAGCCCCGT CTTTACTAGA AATACAAAAA TTAGACGAGC 300
GTGGTGGTGG ACACCTGTGT TCCCAGCTAC TTGGGAGGCT GAGGCAGGAG ACTGGCTGGA 360
ACCAGGGAGG TAGAGGTTGC AGTGAGCTGA GATCGTGCCA CTGCACTCCA GCCTGGGTGA 420 CAGAGTGAGA CTCCATCATA AATAAATAAA TAAATAAATG GGTCACATTA AGCCTTTAAA 480 AAAAAAAAAA AAA - 493
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2682 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
GGTTCCCAGA AGAGTTTGCG ACGTGGTAAA GAAATAAGGC GAGTACACAA GCGAAGACTT 60
TCCAGCTCAG AGAGTGAAGA GAGCTATTTG TCCAAGAACT CTGAAGATGA TGAGCTAGCT 120
AAAGAATCAA AGCGGTCAGT TCGAAAGCGG GGCCGAAGCA CAGACGAGTA TTCAGAAGCA 180
GATGAGGAGG AGGAGGAAGA RGAAGGCAAA CCATCCCGCA AACGGCTACA CCGGATTGAG 240
ACGGATGAGG ARGAGAGTTG TGACAATGCT CATGGAGATG CAAATCAGCC TGCCCGTGAC 300
AGCCAGCCTA GGGTCCTGCC CTCAGAACAA GAGAGCACCA AGAAGCCCTA CCGGATAGAA 360
AGTGATGAGG AAGAGGACTT TGAAAATGTA GGCAAAGTGG GGAGCCCATT GGACTATAGC 420
TTAGTGGACT TACCTTCAAC CAATGGACAG AGCCCTGGCA AAGCCATTGA GAACTTGATT 480
GGCAAGCCTA CTGAGAAGTC TCAGACCCCC AAGGACAACA GCACAGCCAG TGCAAGCCTA 540
GCYTCCCAAT GGGACAAGTG GTGGGCAGGA GGCAGGAGCA CCAGAAGAGG AGGAAGATGA 600
GCTTTTGAGA GTGACTGACC TTGTTGATTA TGTCTGTAAC AGTGAACAGT TATAAGACTT 660
TTTTTCCATT TTTGTGCTAA TTTATTCCAC GGTAGCTCTC ACACCAGCGG GCCAGTTATT 720
AAAAGCTGTT TAATTTTTCC TAGAAAACTC CACTACAGAA TGACTTTTAG AAGAAAAATT 780
TCAACAAATC CTGAAGTCTT TCTGTGAAGT GACCAGTTCT GAACTTTGAA GATAAATAAT 840
TGCTGTAAAT TCCTTTTGAT TTTCTTTTTC CAGGTTCATG GTCCTTGGTA ATTTCATTCA 900
TGGAAAAAAA TCTTATTATA ATAACAACAA AGATTTGTAT ATTTTTGACT TTATATTTCC 960
TGAGCTCTCC TGACTTTGTG AAAAAGGGTG ATGAAAATGC ATTCCGAATC TGTGAGGGCC 1020
CAAAACAGAA TTTAGGGGTG GGTGAAAGCA CTTGTGCTTT AGCTTTTTCA TATTAAATAT 1080 ATATTATATT TAAACATTCA TGGCATAGAT GATGATTTAC AGACAATTTA AAAGTTCAAG 1140
TCTGTACTGT TACAGTTTGA GAATTGT GA TAACATCATA CAT AGTCAT TTAGTAACAG 1200
CCTTTGTGAA ATGAACTTGT TTACTATTGG AGATAACCAC ACTTAATAAA GAAGAGACAG 1260
TGAAAGTACC ATCATAATTA ACCTAAATTT TTGTTATAGC AGAGTTTCTT GTTTAAAAAA 1320
AAAWAAAAWG CRKCYGMAAA GCATTTGTAC AGTAAAATGT ATAATGAAGC TTTGCCAACC 1380
AGACTGTGCT AGCAACAAAT TTTTTTAAAT AAGCTTTATG CAGTGGTAAT AAGGTGGCCT 1440
CAAATATATT GTGTCTGATG GAGAGTTATT AGTGAAATGA ATGTGGTCTT TCTTAAGGCC 1500
TGGGTGGACT GTAAACTTTG CCAATAGTAT AACTCTTGTC TTCTGGCCAC TTGATGTTTA 1560
AATATCTGAA ATATCATTTT GAAAAAAATA CATCTATATA TAACATACAT GAAGAGATGC 1620
TAAGCTGACA GTGATATTTT AGCACATTTG AAGACTGGGA AGAGATTTTC AGGTGAATTT 1680
TAACTGGTCT ATTCTTGCCC TTAGTATCTA CTTCAAATTG AAGTCTACAA ACAAAGCAGT 1740
TCCTTTGGGA GGTTTTTAGT TTGAGTTTTA GCGTGTGTGT GTGTTTGTGT GTGTGCGTGT 1800
GCGTGTGTGT GTGTGTTGGA ATTTCCTATC TGCCTGGATA TATTAGCAGA GTTTGAATGT 1860
AGTTTTGGCC TTTGGCCATT AGACTTCTAT TAAAATTCAT TAATAGTCAT ACAACCAACA 1920
TAGAGTTGAA TGAGAACTGC CGATGTAATT AATAGGCATG ACATCCATTT CAAACATCTC 1980
AACACTTTAA AGAAAAGCCC TTTGTTTCAA GAAAAAAGGG TTTGTAACTA ACTAAATACC 2040
TAACATGTAA TTGACACTAA AATATGAACT TTGTCTTATT TAGTTTCTGT TATAGCTGTA 2100
AAATTTCAGG CAGAGCCATA ACATTGTACA GAGTGTAGCA CTTGTGATTA AACCTAGCCT 2160
GTTAAATCCT GAAACCTTCA ACCATTACTT CTGTGAATAC TTTAGCCCTG GGATTTGGGT 2220
TTTTCTGTTC CGGTGTTGTG TCTGTTGCCG GCAATGGACA CACCATATCT GCTGCTGGCC 2280
CAAGGAACGT CATTAATTTT TCTTTCCAAA TTAAGTATTA TGTGCTAGTC AGTGTATAGT 2340
AAAGCACTTC TCTTTTTTAT TACTAAAAAG CTGGCATTAG ATTTGCATTA TAAATACCTC 2400
TCTAGGAACT TTATACTCCT TTTCCTTCTT CAACAGGTAT TGCCCTTAAA TCTTATCTTT 2460
TGGCCTTGAA AGTTTATAGC TATTGTTTTT CAGTTGTTCG TTGTTTTGTT TTGTTTCACT 2520
TTAGTTCTGT AGTACCTGCC CATTAATATT TTTGCTTTGA TTCTAGCAAT GTGTATGTAT 2580
CTGTATAAAA AATAAAATAA TGAAAGCAAC CTAAAAATAG GATGCACCAA TTAAAAAAAA 2640
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA 2682 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
Met Glu Lys Asn Leu lie lie lie Thr Thr Lys lie Cys lie Phe Leu 1 5 10 15
Thr Leu Tyr Phe Leu Ser Ser Pro Asp Phe Val Lys Lys Gly Asp Glu 20 25 30
Asn Ala Phe Arg lie Cys Glu Gly Pro Lys Gin Asn Leu Gly Val Gly 35 40 45
Glu Ser Thr Cys Ala Leu Ala Phe Ser Tyr 50 55
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2522 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
GCCGAGCGCC CGCGCCGCCG CTGCCTCTGT CCTCCGCGCG CTGCTCAGCT GAAGGCGCAC 60
AGGATTCAAT TACTGGACTT GTCAACTCTG CCAGTGTACG TGCCATTTCT CTTCCACTAT 120
GAGAGGACCG ATTGTATTGC ACATTTGTCT GGCTTTCTGT AGCCTTCTGC TTTTCAGCGT 180
TGCCACACAA TGTCTGGCCT TCCCCAAAAT AGAAAGGAGG AGGGAGATAG CACATGTTCA 240
TGCGGAAAAA GGGCAGTCCG ATAAGATGAA CACCGATGAC CTAGAAAATA GCTCTGTTAC 300
CTCAAAGCAG ACTCCCCAAC TGGTGGTCTC TGAAGATCCA ATGATGATGT CAGCAGTACC 360
ATCGGCAACA TCATTAAATA AAGCATTCTC GATTAACAAA GAAACCCAGC CTGGACAAGC 420
TGGGCTCATG CAAACAGAAC GCCCTGGTGT TTCCACACYT ACTGAGTCAG GTGTCCCCTC 480 AGCTGAAGAA GTATTTGGTT CCAGCCAGCC AGAGAGAATA TCTCCTGAAA GTGGACTTGC 540
CAAGGCCATG TTAACCATTG CTATCACTGC GACTCCTTCT CTGACTGTTG ATGAAAAGGA 600
GGAACTCCTT ACAAGCACTA ACTTTCAGCC CATTGTAGAA GAGATCACAG AAACCACAAA 660
AGGTTTTCTG AAGTATATGG ATAATCAATC ATTTGCAACT GAAAGTCAGG AAGGAGTTGG 720
TTTGGGACAT TCACCTTCAT CCTATGTGAA TACTAAGGAA ATGCTAACCA CCAATCCAAA 780
GACTGAGAAA TTTGAAGCAG ACACAGACCA CAGGACAACT TCTTTTCCTG GTGCTGAGTC 840
CACAGCAGGC AGTGAGCCTG GAAGCCTCAC CCCTGATAAG GAGAAGCCTT CGCAGATGAC 900
AGCTGATAAC ACCCAGGCTG CTGCCACCAA GCAACCACTC GAAACTTCCG AGTACACCCT 960
GAGTGTTGAG CCAGAAACTG ATAGTCTGCT GGGAGCCCCA GAAGTCACAG TGAGTGTCAG 1020
CACAGCTGTT CCAGCTGCCT CTGCCTTAAG TGATGAGTGG GATGACACCA AATTAGAGAG 1080
TGTAAGCCGG ATAAGGACCC CCAAGCTTGG AGACAATGAA GAGACTCAGG TGAGAACGGA 1140
GATGTCTCAG ACAGCACAAG TAAGCCATGA GGGTATGGAA GGAGGCCAGC CTTGGACAGA 1200
GGCTGCACAG GTGGCTCTGG GGCTGCCTGA AGGGGAAACA CACACGGGCA CAGCCCTGCT 1260
AATAGCGCAT GGGAATGAGA GATCACCTGC TTTCACTGAT CAAAGTTCCT TTACCCCCAC 1320
AAGTCTGATG GAAGACATGA AAGTTTCCAT TGTGAACTTG CTCCAAAGTA CGGGAGACTT 1380
CACGGAATCC ACCAAGGAAA ACGATGCCCT GTTTTTCTTA GAAACCACTG TTTCTGTCTC 1440
TGTATATGAG TCTGAGGCAG ACCAACTGTT GGGAAATACA ATGAAAGACA TCATCACTCA 1500
AGAGATGACA ACAGCTGTTC AAGAGCCAGA TGCCACTTTA TCCATGGTGA CACAAGAGCA 1560
GGTTGCTACC CTCGAGCTTA TCAGAGACAG TGGCAAGACT GAGGAAGAAA AGGAGGACCC 1620
CTCTCCTGTG TCTGACGTTC CTGGTGTTAC TCAGCTGTCA AGAAGATGGG AGCCTCTGGC 1680
CACTACAATT TCAACTACAG TCGTCCCTTT GTCTTTTGAA GTTACTCCCA CTGTGGAAGA 1740
ACAAATGGAC ACAGTCACAG GGCCAAATGA GGAGTTCACA CCAGTTCTGG GATCTCCAGT 1800
GACACCTCCT GGAATAATGG TGGGGGAACC CAGCATTTCC CCTGCACTTC CTGCTTTGGA 1860
GGCATCCTCT GAGAGAAGAA CTGTTGTTCC ATCTATTACT CGTGTTAATA CAGCTGCCTC 1920
ATATGGCCTG GACCAACTTG AATCTGAAGA GGGACAAGAA GATGAGGATG AAGAGGATGA 1980
AGAAGATGAA GATGAAGAAG AGGAAGATGA GGAAGAAGAT GAGGAAGATA AAGATGCAGA 2040
CTCGCTGGAT GAGGGCTTGG ATGGTGACAC TGAGCTGCCA GGTTTTACCC TCCCTGGTAT 2100
CACATCCCAG GAACCAGGCT TAGAGGAGGG AAACATGGAC CTGTTGGAGG GAGCTACCTA 2160 CCAGGTGCCA GATGCCYTCG AGTGGGAACA GCAGAATCAA GGCCTGGTGA GAAGCTGGAT 2220
GGAAAAATTM AAAGACAAGG CTGGTTACAT GTCTGGGATG CTGGTGCCTG TAGGGGTTGG 2280
GATAGCTGGA GCCTTGTTCA TCTTGGGAGC CCTCTACAGC ATTAAGGTTA TGAATCGCCG 2340
AAGGAGAAAT GGCTTCAAAA GGCATAAAAG AAAGCAGAGA GAATTCAACA GCATGCAAGA 2400
TCGAGTAATG CTCTTAGCCG ACAGCTCTGA AGATGAATTT TGAATTGGAC TGGGTTTTAA 2460
TTGGGATATT CAACGATGCT ACTATTCTAA TTTTTATTTT GGAGCAGAAA AAAAAAAAAA 2520
AA 2522 (2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 774 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
Met Arg Gly Pro lie Val Leu His lie Cys Leu Ala Phe Cys Ser Leu 1 5 10 15
Leu Leu Phe Ser Val Ala Thr Gin Cys Leu Ala Phe Pro Lys lie Glu 20 25 30
Arg Arg Arg Glu lie Ala His Val His Ala Glu Lys Gly Gin Ser Asp 35 40 45
Lys Met Asn Thr Asp Asp Leu Glu Asn Ser Ser Val Thr Ser Lys Gin 50 55 60
Thr Pro Gin Leu Val Val Ser Glu Asp Pro Met Met Met Ser Ala Val 65 70 75 80
Pro Ser Ala Thr Ser Leu Asn Lys Ala Phe Ser lie Asn Lys Glu Thr 85 90 95
Gin Pro Gly Gin Ala Gly Leu Met Gin Thr Glu Arg Pro Gly Val Ser 100 105 110
Thr Xaa Thr Glu Ser Gly Val Pro Ser Ala Glu Glu Val Phe Gly Ser 115 120 125
Ser Gin Pro Glu Arg lie Ser Pro Glu Ser Gly Leu Ala Lys Ala Met 130 135 140 Leu Thr lie Ala lie Thr Ala Thr Pro Ser Leu Thr Val Asp Glu Lys 145 150 155 160
Glu Glu Leu Leu Thr Ser Thr Asn Phe Gin Pro lie Val Glu Glu lie 165 170 175
Thr Glu Thr Thr Lys Gly Phe Leu Lys Tyr Met Asp Asn Gin Ser Phe 180 185 190
Ala Thr Glu Ser Gin Glu Gly Val Gly Leu Gly His Ser Pro Ser Ser 195 200 205
Tyr Val Asn Thr Lys Glu Met Leu Thr Thr Asn Pro Lys Thr Glu Lys 210 215 220
Phe Glu Ala Asp Thr Asp His Arg Thr Thr Ser Phe Pro Gly Ala Glu 225 230 235 240
Ser Thr Ala Gly Ser Glu Pro Gly Ser Leu Thr Pro Asp Lys Glu Lys 245 250 255
Pro Ser Gin Met Thr Ala Asp Asn Thr Gin Ala Ala Ala Thr Lys Gin 260 265 270
Pro Leu Glu Thr Ser Glu Tyr Thr Leu Ser Val Glu Pro Glu Thr Asp 275 280 285
Ser Leu Leu Gly Ala Pro Glu Val Thr Val Ser Val Ser Thr Ala Val 290 295 300
Pro Ala Ala Ser Ala Leu Ser Asp Glu Trp Asp Asp Thr Lys Leu Glu 305 310 315 320
Ser Val Ser Arg lie Arg Thr Pro Lys Leu Gly Asp Asn Glu Glu Thr 325 330 335
Gin Val Arg Thr Glu Met Ser Gin Thr Ala Gin Val Ser His Glu Gly 340 345 350
Met Glu Gly Gly Gin Pro Trp Thr Glu Ala Ala Gin Val Ala Leu Gly 355 360 365
Leu Pro Glu Gly Glu Thr His Thr Gly Thr Ala Leu Leu lie Ala His 370 375 380
Gly Asn Glu Arg Ser Pro Ala Phe Thr Asp Gin Ser Ser Phe Thr Pro 385 390 395 400
Thr Ser Leu Met Glu Asp Met Lys Val Ser lie Val Asn Leu Leu Gin 405 410 415
Ser Thr Gly Asp Phe Thr Glu Ser Thr Lys Glu Asn Asp Ala Leu Phe 420 425 430
Phe Leu Glu Thr Thr Val Ser Val Ser Val Tyr Glu Ser Glu Ala Asp 435 440 445
Gin Leu Leu Gly Asn Thr Met Lys Asp lie lie Thr Gin Glu Met Thr 450 455 460
Thr Ala Val Gin Glu Pro Asp Ala Thr Leu Ser Met Val Thr Gin Glu 465 470 475 480
Gin Val Ala Thr Leu Glu Leu lie Arg Asp Ser Gly Lys Thr Glu Glu 485 490 495
Glu Lys Glu Asp Pro Ser Pro Val Ser Asp Val Pro Gly Val Thr Gin 500 505 510
Leu Ser Arg Arg Trp Glu Pro Leu Ala Thr Thr lie Ser Thr Thr Val 515 520 525
Val Pro Leu Ser Phe Glu Val Thr Pro Thr Val Glu Glu Gin Met Asp 530 535 540
Thr Val Thr Gly Pro Asn Glu Glu Phe Thr Pro Val Leu Gly Ser Pro 545 550 555 560
Val Thr Pro Pro Gly lie Met Val Gly Glu Pro Ser lie Ser Pro Ala 565 570 575
Leu Pro Ala Leu Glu Ala Ser Ser Glu Arg Arg Thr Val Val Pro Ser 580 585 590 lie Thr Arg Val Asn Thr Ala Ala Ser Tyr Gly Leu Asp Gin Leu Glu 595 600 605
Ser Glu Glu Gly Gin Glu Asp Glu Asp Glu Glu Asp Glu Glu Asp Glu 610 615 620
Asp Glu Glu Glu Glu Asp Glu Glu Glu Asp Glu Glu Asp Lys Asp Ala 625 630 635 640
Asp Ser Leu Asp Glu Gly Leu Asp Gly Asp Thr Glu Leu Pro Gly Phe 645 650 655
Thr Leu Pro Gly lie Thr Ser Gin Glu Pro Gly Leu Glu Glu Gly Asn 660 665 670
Met Asp Leu Leu Glu Gly Ala Thr Tyr Gin Val Pro Asp Ala Xaa Glu 675 680 685
Trp Glu Gin Gin Asn Gin Gly Leu Val Arg Ser Trp Met Glu Lys Xaa 690 695 700
Lys Asp Lys Ala Gly Tyr Met Ser Gly Met Leu Val Pro Val Gly Val 705 710 715 720
Gly lie Ala Gly Ala Leu Phe lie Leu Gly Ala Leu Tyr Ser lie Lys 725 730 735 Val Met Asn Arg Arg Arg Arg Asn Gly Phe Lys Arg His Lys Arg Lys 740 745 750
Gin Arg Glu Phe Asn Ser Met Gin Asp Arg Val Met Leu Leu Ala Asp 755 760 765
Ser Ser Glu Asp Glu Phe 770
(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2002 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
GGCACGCCGG TACCTGAAGT CCTTCAGAAG TGCACGCCGG GACCAGGATT CCGGGAGGCC 60
GACTCCTCCC TGCCCCACGA ATGCCGGGAA TTGTGGTCTC CGCCGGACGC GAGTTGTGAG 120
ACGGCCCAAG GGGCCGCGGG GTATGCTGGG ACCGCTAGCC CTTCCGGCGC GCCTCAGGAC 180
TTCGGGTCCC CTCACCCCGG GCGGATGCCC AAAGACTCCG CCTTCCCAAG AGCCCCTGCG 240
GCCGGGCGCG AAAATGGCGG CGGCGGCGAC GGCCGGGCGC TCCTGAAGCA GCAGTTATGG 300
AGCTTCCCTC AGGGCCGGGG CCGGAGCGGC TCTTTGACTC GCACCGGCTT CCGGGTGACT 360
GCTTCCTACT GCTCGTGCTG CTGCTCTACG CGCCAGTCGG GTTCTGCCTC CTCGTCCTGC 420
GCCTGTTTCT CGGGATCCAC GTCTTCCTGG TCAGCTGCGC GCTGCCAGAC AGCGTCCTTC 480
GCAGATTCGT AGTGCGGACC ATGTGTGCGG TGCTAGGGCT CGTGGCCCGG CAGGAGGACT 540
CCGGACTCCG GGATCACAGT GTCAGGGTCC TCATTTCCAA CCATGTGACA CCTTTCGACC 600
ACAACATAGT CAATTTGCTT ACCACCTGTA GCACCGTGAG TGAGAGCGAG GCCGAGAGCG 660
CCACGGGGCG GTTCCCTGGG GCCCAGCTGA AGGCCCCCCT GTCCCCACTC GCGTTCCCCA 720
TGGAGGATAC TGAGCCTTAC CCCTAACCCC GATCCTCTAC CCAACATGTC AGTTTTTTTT 780
TTCATTTTCC TCAATATTTT TCTTCTTGCT TTCTCTTCTC CTGGTTCCCA GCCTCTACTC 840
AATAGTCCCC CCAGCTTTGT GTGCTGGTCT CGGGGCTTCA TGGAGATGAA TGGGCGGGGG 900
GAGTTGGTGG AGTCACTCAA GAGATTCTGT GCTTCCACGA GGCTTCCCCC CACTCCTCTG 960 CTGCTATTCC CTGAGGAAGA GGCCACCAAT GGCCGGGAGG GGCTCCTGCG CTTCAGAGTT 1020
TGACAGTTGC CTGTTATAAG GCAGGTGTGA GCTGCTGACT AGGCTGGCTG GATTCCCATC 1080
CTACTTTCTC CTTCCTCTTC TAGTTCCTGG CCATTTTCTA TCCAAGATGT GGTACAACCT 1140
CTTACCCTGC AAGTTCAGAG ACCCCTGGTC TCTGTGACGG TGTCAGATGC CTCCTGGGTC 1200
TCAGAACTGC TGTGGTCACT TTTCGTCCCT TTCACGGTGT ATCAAGTGGC TTCGTCCTGT 1260
TCATCGCCAA CTAGGGGAAG CGAATGAGGA GTTTGCACTC CGTGTACAAC AGCTGGTGGC 1320
CAAGGAATTG GGCCAGACAG GGACACGGCT CACTCCAGCT GACAAAGCAG AGCACATGAA 1380
GCGACAAAGA CACCCCAGAT TGCGCCCCCA GTCAGCCCAG TCTTCTTTCC CTCCCTCCCC 1440
TGGTCCTTCT CCTGATGTGC AACTGGCAAC TCTGGCTCAG AGAGTCAAGG AAGTTTTGCC 1500
CCATGTGCCA TTTGGTGTCA TCCAGAGAGA CCTGGCCAAG ACTGGCTGTG TAGACTTGAC 1560
TATCACTAAT CTGCTTGAGG GGGCCGTAGC TTTCATGCCT GAAGACATCA CCAAGGGAAC 1620
TCAGTCCCTA CCCACAGCCT CTGCCTCCAA GTTTCCCAGC TCTGGCCCGG TGACCCCTCA 1680
GCCAACAGCC CTAACATTTG CCAAGTCTTC CTGGGCCCGG CAGGAGAGCC TGCAGGAGCG 1740
CAAGCAAGCA CTATATGAAT ACGCAAGAAG GAGATTCACA GAGAGACGAG CCCAGGAGGC 1800
TGACTGAGCT CAAAGGAACA GGATGGCACC CAGAGCCGCA GGACGGAGAC TGGGGGCAGC 1860
CCTCACCCAA CTCACAACAG GCTGGATGGG TGGGTGGTAA AAAGGGAAGG ATGAGGCTCC 1920
CCCAATGTCA CATTAAATTC ATGGTTTTCA TTCAAGGVAA AAAAAAAAAA AAAAAAAAAA 1980
AAAAAAAAAA AAAAAAAAAA AA 2002 (2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 206 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
Met Pro Pro Gly Ser Gin Asn Cys Cys Gly His Phe Ser Ser Leu Ser 1 5 10 15
Arg Cys lie Lys Trp Leu Arg Pro Val His Arg Gin Leu Gly Glu Ala 20 25 30
Asn Glu Glu Phe Ala Leu Arg Val Gin Gin Leu Val A-la Lys Glu Leu 35 40 45
Gly Gin Thr Gly Thr Arg Leu Thr Pro Ala Asp Lys Ala Glu His Met 50 55 60
Lys Arg Gin Arg His Pro Arg Leu Arg Pro Gin Ser Ala Gin Ser Ser 65 70 75 80
Phe Pro Pro Ser Pro Gly Pro Ser Pro Asp Val Gin Leu Ala Thr Leu 85 90 95
Ala Gin Arg Val Lys Glu Val Leu Pro His Val Pro Phe Gly Val lie 100 105 110
Gin Arg Asp Leu Ala Lys Thr Gly Cys Val Asp Leu Thr lie Thr Asn 115 120 125
Leu Leu Glu Gly Ala Val Ala Phe Met Pro Glu Asp lie Thr Lys Gly 130 135 140
Thr Gin Ser Leu Pro Thr Ala Ser Ala Ser Lys Phe Pro Ser Ser Gly 145 150 155 160
Pro Val Thr Pro Gin Pro Thr Ala Leu Thr Phe Ala Lys Ser Ser Trp 165 170 175
Ala Arg Gin Glu Ser Leu Gin Glu Arg Lys Gin Ala Leu Tyr Glu Tyr 180 185 190
Ala Arg Arg Arg Phe Thr Glu Arg Arg Ala Gin Glu Ala Asp 195 200 205
(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 819 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
CAATTGGGCC GCGAGTTGTG GTTTAAACCA GGAGTGCGCC GCGTCCGTTC ACCGCGGCCT 60
CAGATGAATG CGGCTGTTAA GACCTGCAAT AATCCAGAAT GGCTACTCTG ATCTATGTTG 120
ATAAGGAAAA TGGAGAACCA GGCACCCGTG TGGTTGCTAA GGATGGGCTG AAGCTGGGGT 180 CTGGACCTTC AATCAAAGCC TTAGATGGGA GATCTCAAGT TTCAACACCA CGTTTTGGCA 240
AAACGTTCGA TGCCCCACCA GCCTTACCTA AAGCTACTAG AAAGGCTTTG GGAACTGTCA 300
ACAGAGCTAC AGAAAAGTCT GTAAAGACCA AGGGACCCCT CAAACAAAAA CAGCCAAGCT 360
TTTCTGCCAA AAAGATGACT GAGAAGACTG TTAAAGCAAA AAGCTCTGTT CCTGCCTCAG 420
ATGATGCCTA TCCAGAAATA GAAAAATTCT TTCCCTTCAA TCCTCTAGAC TTTGAGAGTT 480
TTGACCTGCC TGAAGAGCAC CAGATTGCGC ACCTCCCCTT GAGTGGAGTG CCTCTCWTGA 540
TCCTTGACGA GGAGAGAGAG CTTGAAAAGC TGTTTCAGCT GGGCCCCCCT TCACCTGTGA 600
AGATGCCCTC TCCACCATGG GAATCCAATC TGTTGCAGTC TCCTTCAAGC ATTCTGTCGA 660
CCCTGGATGT TGAATTGCCA CCTGTTTGCT GTGACATAGA TATTTAAATT TCTTAGTGCT 720
TCAGAGTTTG TGTGTATTTG TATTAATAAA GCATTCTTTA ACAGAAAAAA AAAAAAAAAA 780
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 819 (2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 146 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
Met Ala Thr Leu lie Tyr Val Asp Lys Glu Asn Gly Glu Pro Gly Thr 1 5 10 15
Arg Val Val Ala Lys Asp Gly Leu Lys Leu Gly Ser Gly Pro Ser lie 20 25 30
Lys Ala Leu Asp Gly Arg Ser Gin Val Ser Thr Pro Arg Phe Gly Lys
35 40 45
Thr Phe Asp Ala Pro Pro Ala Leu Pro Lys Ala Thr Arg Lys Ala Leu 50 55 60
Gly Thr Val Asn Arg Ala Thr Glu Lys Ser Val Lys Thr Lys Gly Pro 65 70 75 80
Leu Lys Gin Lys Gin Pro Ser Phe Ser Ala Lys Lys Met Thr Glu Lys 85 90 95 Thr Val Lys Ala Lys Ser Ser Val Pro Ala Ser Asp Asp Ala Tyr Pro 100 105 110
Glu lie Glu Lys Phe Phe Pro Phe Asn Pro Leu Asp Phe Glu Ser Phe 115 120 125
Asp Leu Pro Glu Glu His Gin lie Ala His Leu Pro Leu Ser Gly Val 130 135 140
Pro Leu 145
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: TNTCCTGCCTC AGCTGCCTCT CTGTGTAA 29
(2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CNCACTGCCCT CCTTCTCCCA TAGGTACT 29
(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: GNAATAAGCAT GATGCTCTAC AAGGAAAG 29
(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: TNGGTGCCATG ATTCTGAGTG CCCTTTGC 29
(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: GNATATGTCAC TGTCATCTCC TCTGCTGC 29
(2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: ANAAGCTTCAT CCAGTAAGAT ATTTGCAC 29
(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: ANTTCAGAACT GGTCACTTCA CAGAAAGA 29
(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GNATTCACATA GGATGAAGGT GAATGTCC 29
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: ANTAGAGGCTG GGAACCAGGA GAAGAGAA 29
(2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: TNTTGCAGGTC TTAACAGCCG CATTCATC 29
(2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
Met Glu Leu Pro Ser Gly Pro Gly Pro Glu Arg Leu Phe Asp Ser His 1 5 10 15
Arg Leu Pro Gly Asp Cys Phe Leu Leu Leu Val Leu Leu Leu Tyr Ala 20 25 30
Pro Val Gly Phe Cys Leu Leu Val Leu Arg Leu Phe Leu Gly He His 35 40 45
Val Phe Leu Val Ser Cys Ala Leu Pro Asp Ser Val Leu Arg Arg Phe 50 55 60
Val Val Arg Thr Met Cys Ala Val Leu Gly Leu Val Ala Arg Gin Glu 65 70 75 80 Asp Ser Gly Leu Arg Asp His Ser Val Arg Val Leu He Ser Asn His 85 90 95
Val Thr Pro Phe Asp His Asn He Val Asn Leu Leu Thr Thr Cys Ser 100 105 110
Thr
(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Ser Gin Pro Leu Leu Asn Ser Pro Pro Ser Phe Val Cys Trp Ser Arg 1 5 10 15
Gly Phe Met Glu Met Asn Gly Arg Gly Glu Leu Val Glu Ser Leu Lys 20 25 30
Arg Phe Cys Ala Ser Thr Arg Leu Pro Pro Thr Pro Leu Leu Leu Phe 35 40 45
Pro Glu Glu Glu Ala Thr Asn Gly Arg Glu Gly Leu Leu Arg Phe 50 55 60
(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
Ser Ser Trp Pro Phe Ser He Gin Asp Val Val Gin Pro Leu Thr Leu 1 5 10 15
Gin Val Gin Arg Pro Leu Val Ser Val Thr Val Ser Asp Ala Ser Trp 20 25 30
Val Ser Glu Leu Leu Trp Ser Leu Phe Val Pro Phe Thr Val Tyr Gin 35 40 45
Val

Claims

What is claimed is:
1. An isolated polynucleotide selected from the group .consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 170 to nucleotide 322;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 218 to nucleotide 322;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 1814 to nucleotide 2355;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bl209_10 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 20 to amino acid 29 of SEQ ID NO:2;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
(a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
(b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. The protein of claim 6 comprising a mature protein.
8. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2;
(b) fragments of the amino acid sequence of SEQ ID NO:2 comprising the amino acid sequence from amino acid 20 to amino acid 29 of SEQ ID NO:2; and
(c) the amino acid sequence encoded by the cDNA insert of clone bl209_10 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
9. The protein of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
10. A composition comprising the protein of claim 8 and a pharmaceutically acceptable carrier.
11. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 10.
12. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:l.
13. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 102 to nucleotide 1295;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 162 to nucleotide 1295;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 804 to nucleotide 1184;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone crll62_25 deposited under accession number ATCC 98379;
(f) a polynucleotide encodi g the full-length protein encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone crll62_25 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO:4;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
14. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:4;
(b) the amino acid sequence of SEQ ID NO:4 from amino acid 236 to amino acid 361;
(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising the amino add sequence from amino acid 194 to amino acid 203 of SEQ ID NO:4; and
(d) the amino acid sequence encoded by the cDNA insert of clone crll62_25 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
15. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.
16. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 351 to nucleotide 842;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 687 to nucleotide 842;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 689;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379; (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dh40_3 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:6;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
17. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:6;
(b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 113;
(c) fragments of the amino acid sequence of SEQ ID NO:6 comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:6; and
(d) the amino acid sequence encoded by the cDNA insert of clone dh40_3 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
18. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:5.
19. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 2205 to nucleotide 2882;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 2262 to nucleotide 2882;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 2494 to nucleotide 3120;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone di39_9 deposited under accession number ATCC 98379;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone di39_9 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 108 to amino acid 117 of SEQ ID NO:8;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
20. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:8; (b) fragments of the amino acid sequence of SEQ ID NO:8 comprising the amino acid sequence from amino acid 108 to amino acid 117 of SEQ ID NO: 8; and
(c) the amino acid sequence encoded by the cDNA insert of clone di39_9 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
21. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:7.
22. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 40 to nucleotide 1503;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 863 to nucleotide 1377;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dt674_2 deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:10;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
23. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 10;
(b) the amino acid sequence of SEQ ID NO:10 from amino acid 277 to amino acid 446;
(c) fragments of the amino acid sequence of SEQ ID NO:10 comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO: 10; and
(d) the amino acid sequence encoded by the cDNA insert of clone dt674_2 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
24. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.
25. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:ll;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 11 from nucleotide 85 to nucleotide 450;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:ll from nucleotide 217 to nucleotide 450;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone eh61_l deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone eh61_l deposited under accession number ATCC 98379; (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
26. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:12;
(b) the amino acid sequence of SEQ ID NO: 12 from amino acid 9 to amino acid 94;
(c) fragments of the amino acid sequence of SEQ ID NO:12 comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO:12; and
(d) the amino acid sequence encoded by the cDNA insert of clone eh61_l deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
27. An isolated gene corresponding to the cDNA sequence of SEQ ID NO: 11 and SEQ ID NO:13.
28. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14 from nucleotide 900 to nucleotide 1073;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 14 from nucleotide 544 to nucleotide 1022;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone fg265_l deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone f g265_l deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fg265_l deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:15 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:15;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
29. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 15;
(b) the amino acid sequence of SEQ ID NO:15 from amino acid 1 to amino acid 41; (c) fragments of the amino acid sequence of SEQ ID NO:15 comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO: 15; and
(d) the amino acid sequence encoded by the cDNA insert of clone fg265_l deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
30. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:14.
31. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 119 to nucleotide 2440;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 200 to nucleotide 2440;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 460 to nucleotide 1153;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fp273_10 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:17;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 17 having biological activity, the fragment comprising the amino acid sequence from amino acid 382 to amino acid 391 of SEQ ID NO:17; (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
32. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 17;
(b) the amino acid sequence of SEQ ID NO:17 from amino acid 115 to amino acid 345;
(c) fragments of the amino acid sequence of SEQ ID NO:17 comprising the amino acid sequence from amino acid 382 to amino acid 391 of SEQ ID NO:17; and
(d) the amino acid sequence encoded by the cDNA insert of clone fp273_10 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
33. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:16.
34. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 1187 to nucleotide 1804;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 674 to nucleotide 1014;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone fy243_8 deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379; (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fy243_8 deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:19;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
35. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 19;
(b) the amino acid sequence of SEQ ID NO: 19 from amino acid 21 to amino acid 69;
(c) fragments of the amino acid sequence of SEQ ID NO: 19 comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:19; and
(d) the amino acid sequence encoded by the cDNA insert of clone fy243_8 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
36. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:18.
37. An isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 99 to nucleotide 536;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 1 to nucleotide 370;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ga205_4 deposited under accession number ATCC 98379;
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:21;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
38. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:21;
(b) the amino acid sequence of SEQ ID NO:21 from amino acid 1 to amino acid 90; (c) fragments of the amino acid sequence of SEQ ID NO:21 comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:21; and
(d) the amino acid sequence encoded by the cDNA insert of clone ga205_4 deposited under accession number ATCC 98379; the protein being substantially free from other mammalian proteins.
39. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:20.
PCT/US1998/006176 1997-03-28 1998-03-27 Secreted proteins and polynucleotides encoding them WO1998044113A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98912112A EP0970209A1 (en) 1997-03-28 1998-03-27 Secreted proteins and polynucleotides encoding them
CA002285447A CA2285447A1 (en) 1997-03-28 1998-03-27 Secreted proteins and polynucleotides encoding them
AU65908/98A AU6590898A (en) 1997-03-28 1998-03-27 Secreted proteins and polynucleotides encoding them
JP54187998A JP2002512512A (en) 1998-03-25 1998-03-27 Secreted proteins and polynucleotides encoding them

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82333097A 1997-03-28 1997-03-28
US08/823,330 1997-03-28
US09/047,661 1998-03-25

Publications (1)

Publication Number Publication Date
WO1998044113A1 true WO1998044113A1 (en) 1998-10-08

Family

ID=25238456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006176 WO1998044113A1 (en) 1997-03-28 1998-03-27 Secreted proteins and polynucleotides encoding them

Country Status (2)

Country Link
AU (1) AU6590898A (en)
WO (1) WO1998044113A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939124A2 (en) * 1998-02-24 1999-09-01 Smithkline Beecham Plc MGBP1 sequences
WO2000008057A2 (en) * 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
WO2000032633A1 (en) * 1998-12-02 2000-06-08 Icos Corporation Novel adhesion molecule and methods of use
WO2000040721A1 (en) * 1998-12-31 2000-07-13 Schering Corporation Monocyte-derived nucleic acids and related compositions and methods
WO2001051641A1 (en) * 2000-01-13 2001-07-19 Tularik Inc. Irak-4: compositions and methods of use
EP1134292A2 (en) * 2000-03-17 2001-09-19 Tosoh Corporation Oligonucleotides for detection of vibrio parahaemolyticus and detection method for vibrio parahaemolyticus using the same oligonucleotides
EP1222205A1 (en) * 1999-10-18 2002-07-17 Texas Biotechnology Corporation POLYNUCLEOTIDES ENCODING HUMAN AND MURINE ADHESION PROTEINS (BIgR)
US7999078B2 (en) 1996-12-06 2011-08-16 Schering Corporation Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Database EMBL, entry HS172310, Accession number N80172, 5 April 1996 100% identity to Seq.ID:1 nt.1951-2347 reverse orientation *
Database EMBL, entry HS620267, Accession number N29620, 6 January 1996 99% identity to Seq.ID:1 nt.1948-2333 reverse orientation *
Database EMBL, entry HS622277, Accession number N41622, 27 January 1996 98% identity to Seq.ID:1 nt.1718-2236 *
Database EMBL, entry HS981289, Accession number N52981, 31 January 1997 98% identity to Seq.ID:1 nt.1888-2344 reverse orientation *
Database EMBL, entry HSN93579, Accession number N93579, 26 August 1996 100% identity to Seq.ID:1 nt.2211-2355 reverse orientation *
See also references of EP0970209A1 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999078B2 (en) 1996-12-06 2011-08-16 Schering Corporation Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor
EP0939124A3 (en) * 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
EP0939124A2 (en) * 1998-02-24 1999-09-01 Smithkline Beecham Plc MGBP1 sequences
US6512095B2 (en) 1998-08-07 2003-01-28 Immunex Corp. Molecules designated B7L-1
WO2000008057A2 (en) * 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
WO2000008057A3 (en) * 1998-08-07 2000-05-18 Immunex Corp Molecules designated b7l-1
US7939640B2 (en) 1998-08-07 2011-05-10 Immunex Corporation Antibodies that bind B7L-1
WO2000032633A1 (en) * 1998-12-02 2000-06-08 Icos Corporation Novel adhesion molecule and methods of use
WO2000040721A1 (en) * 1998-12-31 2000-07-13 Schering Corporation Monocyte-derived nucleic acids and related compositions and methods
JP2002534087A (en) * 1998-12-31 2002-10-15 シェーリング コーポレイション Monocyte-derived nucleic acids and related compositions and methods
US8026351B2 (en) 1998-12-31 2011-09-27 Schering Corporation Monocyte-derived nucleic acids and related compositions and methods
US8426144B2 (en) 1998-12-31 2013-04-23 Merck & Sharp & Dohme Corp. Monocyte-derived nucleic acids and related compositions and methods
US6774214B1 (en) 1998-12-31 2004-08-10 Schering Corporation Monocyte-derived homolog of FDF03 protein
JP4629873B2 (en) * 1998-12-31 2011-02-09 シェーリング コーポレイション Monocyte-derived nucleic acids and related compositions and methods
US7932357B2 (en) 1998-12-31 2011-04-26 Schering Corporation FDF-03 S1 antigen-antibody complex
EP1770160A1 (en) * 1998-12-31 2007-04-04 Schering Corporation Monocyte-derived nucleic acids and related compositions and methods
EP1222205A1 (en) * 1999-10-18 2002-07-17 Texas Biotechnology Corporation POLYNUCLEOTIDES ENCODING HUMAN AND MURINE ADHESION PROTEINS (BIgR)
EP1222205A4 (en) * 1999-10-18 2004-03-31 Texas Biotechnology Corp POLYNUCLEOTIDES ENCODING HUMAN AND MURINE ADHESION PROTEINS (BIgR)
JP2004500074A (en) * 2000-01-13 2004-01-08 トゥラリック　インコーポレイテッド IRAK-4: Composition and method of use
US7235635B2 (en) 2000-01-13 2007-06-26 Amgen Inc. IRAK-4: compositions and methods of use
AU783742B2 (en) * 2000-01-13 2005-12-01 Amgen, Inc. IRAK-4: compositions and methods of use
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
WO2001051641A1 (en) * 2000-01-13 2001-07-19 Tularik Inc. Irak-4: compositions and methods of use
EP1134292A3 (en) * 2000-03-17 2003-12-10 Tosoh Corporation Oligonucleotides for detection of vibrio parahaemolyticus and detection method for vibrio parahaemolyticus using the same oligonucleotides
EP1134292A2 (en) * 2000-03-17 2001-09-19 Tosoh Corporation Oligonucleotides for detection of vibrio parahaemolyticus and detection method for vibrio parahaemolyticus using the same oligonucleotides

Also Published As

Publication number Publication date
AU6590898A (en) 1998-10-22

Similar Documents

Publication Publication Date Title
EP0998490A2 (en) Secreted proteins and polynucleotides encoding them
WO1998042739A2 (en) Secreted proteins and polynucleotides encoding them
EP0977853A1 (en) Secreted proteins and polynucleotides encoding them
WO1998040485A1 (en) Human secreted protein, ba3.1, and polynucleotides encoding same
EP1075487A1 (en) Secreted proteins and polynucleotides encoding them
WO1998044113A1 (en) Secreted proteins and polynucleotides encoding them
EP1012261A1 (en) Secreted proteins and polynucleotides encoding them
WO1999041284A1 (en) Secreted proteins and polynucleotides encoding them
WO1998041539A2 (en) Secreted proteins and polynucleotides encoding them
WO1999053045A1 (en) Secreted proteins and polynucleotides encoding them
WO1999026973A1 (en) Secreted proteins and polynucleotides encoding them
EP0972026A2 (en) Secreted proteins and polynucleotides encoding them
EP1007660A2 (en) Secreted proteins and polynucleotides encoding them
EP1017719A1 (en) Secreted proteins and polynucleotides encoding them
WO1998030582A2 (en) Secreted proteins and polynucleotides encoding them
EP1064302A1 (en) Secreted proteins and polynucleotides encoding them
EP0970209A1 (en) Secreted proteins and polynucleotides encoding them
WO1998053065A1 (en) Human semaphorin e and polynucleotides encoding it
EP1037970A1 (en) Secreted proteins and polynucleotides encoding them
WO1998030584A2 (en) Secreted proteins and polynucleotides encoding them
EP1012263A1 (en) Secreted proteins and polynucleotides encoding them
CA2293825A1 (en) Secreted proteins and polynucleotides encoding them
EP1177440A1 (en) Secreted proteins and polynucleotides encoding them
WO1998056805A1 (en) Secreted proteins and polynucleotides encoding them
EP1036087A1 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2285447

Country of ref document: CA

Ref country code: CA

Ref document number: 2285447

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998912112

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998912112

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998912112

Country of ref document: EP